<html lang="en" class="pb-page js" data-request-id="94d6d397f5c677f0-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d6d397f5c677f0-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/MdqGCESQAzTDkZoEHXV0TW6xXDlphC9KZAV8YoF3lHpaPSApwFiGMMTKe889mlhj_ZgLJy2e0iWHLne8wVraeg=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d6d397f5c677f0-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.9461094977692365"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="Specialties" content="Hematology/Oncology|Genetics">
<meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Anemia|Cancer|Treatments in Oncology|Leukemia/Lymphoma|Genetics General"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2119771","title":"Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy","category":"Research","type":"Original Article","topics":"Anemia|Cancer|Treatments in Oncology|Leukemia/Lymphoma|Genetics General","specialties":"Hematology/Oncology|Genetics","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2022-05-26T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"Specialties\" content\u003d\"Hematology/Oncology|Genetics\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Anemia|Cancer|Treatments in Oncology|Leukemia/Lymphoma|Genetics General\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2119771","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d6d397f5c677f0-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy"><meta name="dc.Creator" content="Yao-Chung Liu"><meta name="dc.Creator" content="Junsu Kwon"><meta name="dc.Creator" content="Emiliano Fabiani"><meta name="dc.Creator" content="Zhijian Xiao"><meta name="dc.Creator" content="Yanjing V. Liu"><meta name="dc.Creator" content="Matilde Y. Follo"><meta name="dc.Creator" content="Jinqin Liu"><meta name="dc.Creator" content="Huijun Huang"><meta name="dc.Creator" content="Chong Gao"><meta name="dc.Creator" content="Jun Liu"><meta name="dc.Creator" content="Giulia Falconi"><meta name="dc.Creator" content="Lia Valentini"><meta name="dc.Creator" content="Carmelo Gurnari"><meta name="dc.Creator" content="Carlo Finelli"><meta name="dc.Creator" content="Lucio Cocco"><meta name="dc.Creator" content="Jin-Hwang Liu"><meta name="dc.Creator" content="Adrianna I. Jones"><meta name="dc.Creator" content="Junyu Yang"><meta name="dc.Creator" content="Henry Yang"><meta name="dc.Creator" content="Julie A.I. Thoms"><meta name="dc.Creator" content="Ashwin Unnikrishnan"><meta name="dc.Creator" content="John E. Pimanda"><meta name="dc.Creator" content="Rongqing Pan"><meta name="dc.Creator" content="Mahmoud A. Bassal"><meta name="dc.Creator" content="Maria T. Voso"><meta name="dc.Creator" content="Daniel G. Tenen"><meta name="dc.Creator" content="Li Chai"><meta name="dc.Description" content="Although hypomethylating agents are currently used to treat patients with cancer, whether they can also reactivate and up-regulate oncogenes is not well elucidated.We examined the effect of hypomet..."><meta name="Description" content="Although hypomethylating agents are currently used to treat patients with cancer, whether they can also reactivate and up-regulate oncogenes is not well elucidated.We examined the effect of hypomet..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2022-05-26"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2119771"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202205263862107"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="YXQYoa2119771"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2022 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2119771">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2119771">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2119771">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy | NEJM">
        <meta property="og:title" content="Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2119771">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/acefb654-f828-49eb-a68e-b8bb6a6aea21/nejmoa2119771_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/acefb654-f828-49eb-a68e-b8bb6a6aea21/nejmoa2119771_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Although hypomethylating agents are currently used to treat patients with cancer,
whether they can also reactivate and up-regulate oncogenes is not well elucidated.
We examined the effect of hypome...">
        <meta name="twitter:description" content="Although hypomethylating agents are currently used to treat patients with cancer,
whether they can also reactivate and up-regulate oncogenes is not well elucidated.
We examined the effect of hypome...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="3078">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2119771">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2119771">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:doi\:10.1056/nejm_2022.386.issue-21;wgroup:string:MMS NextGen Website Group;article:article:doi\:10.1056/NEJMoa2119771;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2119771" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2119771" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2119771" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2119771" class="inputDoi"><input type="hidden" value="Y.-C. Liu and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2022;386:1998-2010" class="inputCitation"><input type="hidden" value="05-25-2022" class="inputEPubDate"><input type="hidden" value="May 2022" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d6d397f5c677f0-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li><div style="clear: both;"></div></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Yao-Chung</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Junsu</span> <span property="familyName">Kwon</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Emiliano</span> <span property="familyName">Fabiani</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Zhijian</span> <span property="familyName">Xiao</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Yanjing V.</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Matilde Y.</span> <span property="familyName">Follo</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jinqin</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+19</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Huijun</span> <span property="familyName">Huang</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Chong</span> <span property="familyName">Gao</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jun</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Giulia</span> <span property="familyName">Falconi</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Lia</span> <span property="familyName">Valentini</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Carmelo</span> <span property="familyName">Gurnari</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-6829-5544" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-6829-5544</a></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Carlo</span> <span property="familyName">Finelli</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Lucio</span> <span property="familyName">Cocco</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jin-Hwang</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Adrianna I.</span> <span property="familyName">Jones</span>, <span property="honorificSuffix">B.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Junyu</span> <span property="familyName">Yang</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Henry</span> <span property="familyName">Yang</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Julie A.I.</span> <span property="familyName">Thoms</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ashwin</span> <span property="familyName">Unnikrishnan</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">John E.</span> <span property="familyName">Pimanda</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Rongqing</span> <span property="familyName">Pan</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mahmoud A.</span> <span property="familyName">Bassal</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Maria T.</span> <span property="familyName">Voso</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Daniel G.</span> <span property="familyName">Tenen</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-6423-3888" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-6423-3888</a></span></span>, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Li</span> <span property="familyName">Chai</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-1937-4750" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-1937-4750</a></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-19</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">May 25, 2022</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2022<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">386</span></span>:<span property="pageStart">1998</span>-<span property="pageEnd">2010</span></div><div class="doi">DOI: 10.1056/NEJMoa2119771</div><div class="core-enumeration"><a href="/toc/nejm/386/21"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">386</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">21</span></span></a></div><div><a href="#tab-information">Copyright © 2022</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DYao-Chung%2BLiu%252C%2BJunsu%2BKwon%252C%2BEmiliano%2BFabiani%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D386%26issueNum%3D21%26contentID%3D10.1056%252FNEJMoa2119771%26title%3DDemethylation%2Band%2BUp-Regulation%2Bof%2Ban%2BOncogene%2Bafter%2BHypomethylating%2BTherapy%26publicationDate%3D05%252F26%252F2022" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2119771" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DYao-Chung%2BLiu%252C%2BJunsu%2BKwon%252C%2BEmiliano%2BFabiani%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D386%26issueNum%3D21%26contentID%3D10.1056%252FNEJMoa2119771%26title%3DDemethylation%2Band%2BUp-Regulation%2Bof%2Ban%2BOncogene%2Bafter%2BHypomethylating%2BTherapy%26publicationDate%3D05%252F26%252F2022" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/ab1fca5a-0ba9-4119-b0f2-5927a710feb7/nejmoa2119771.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2119771.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2119771" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2119771" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2119771.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Although hypomethylating agents are currently used to treat patients with cancer, whether they can also reactivate and up-regulate oncogenes is not well elucidated.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We examined the effect of hypomethylating agents on <i>SALL4</i>, a known oncogene that plays an important role in myelodysplastic syndrome and other cancers. Paired bone marrow samples that were obtained from two cohorts of patients with myelodysplastic syndrome before and after treatment with a hypomethylating agent were used to explore the relationships among changes in <i>SALL4</i> expression, treatment response, and clinical outcome. Leukemic cell lines with low or undetectable <i>SALL4</i> expression were used to study the relationship between <i>SALL4</i> methylation and expression. A locus-specific demethylation technology, CRISPR–DNMT1-interacting RNA (CRISPR-DiR), was used to identify the CpG island that is critical for <i>SALL4</i> expression.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph"><i>SALL4</i> up-regulation after treatment with hypomethylating agents was observed in 10 of 25 patients (40%) in cohort 1 and in 13 of 43 patients (30%) in cohort 2 and was associated with a worse outcome. Using CRISPR-DiR, we discovered that demethylation of a CpG island within the 5′ untranslated region was critical for <i>SALL4</i> expression. In cell lines and patients, we confirmed that treatment with a hypomethylating agent led to demethylation of the same CpG region and up-regulation of <i>SALL4</i> expression.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">By combining analysis of patient samples with CRISPR-DiR technology, we found that demethylation and up-regulation of an oncogene after treatment with a hypomethylating agent can indeed occur and should be further studied. (Funded by Associazione Italiana per la Ricerca sul Cancro and others.)</div></section></section></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Interest in epigenetic targeting in cancer treatment is increasing. One example is the use of DNA hypomethylating agents. Two hypomethylating agents, 5-aza-2′-deoxycytidine (decitabine) and 5-azacytidine, are being used clinically. There are many mechanisms of action of these drugs, including irreversibly binding to and inhibiting DNA methyltransferases,<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2 r3 r4" id="body-ref-r4" href-manipulated="true">1-4</a></sup> which result in hypomethylation and up-regulation of genes such as tumor suppressors.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5" id="body-ref-r5" href-manipulated="true" aria-label="Reference 5">5</a></sup> Other major mechanisms of action include incorporation of the hypomethylating agent into newly synthesized DNA, which triggers a DNA-damage response and leads to cytotoxic effects in cancer cells,<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6 r7" id="body-ref-r7" href-manipulated="true">6,7</a></sup> as well as alteration of immune responses.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8 r9 r10" id="body-ref-r10" href-manipulated="true">8-10</a></sup></div><div role="paragraph">We hypothesized that the global effect of treatment with hypomethylating agents would not only contribute to the demethylation of tumor-suppressor genes but may also induce demethylation of oncogenes. To test this theory, we focused on candidate genes with the following features: they are aberrantly expressed in human cancers; they are functionally proved to be oncogenes with the use of methods such as murine models; and DNA methylation may be important for the expression of these genes. This led to our current study, in which we examined how hypomethylating agents could activate the known oncofetal protein, spalt-like transcription factor 4 (SALL4), in patients with myelodysplastic syndrome, as a model to examine the effects of hypomethylating agents on up-regulation of oncogenes.</div><div role="paragraph">SALL4 plays an essential role in myelodysplastic syndrome and acute myeloid leukemia leukemogenesis<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11-1" href-manipulated="true" aria-label="Reference 11">11</a></sup> and tumorigenesis in several solid tumors, including germ-cell tumors, hepatocellular carcinoma, breast cancer, and lung cancer.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12 r13 r14" id="body-ref-r14" href-manipulated="true">12-14</a></sup> During development, SALL4 maintains the self-renewal and pluripotency of embryonic stem cells,<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15" id="body-ref-r15" href-manipulated="true" aria-label="Reference 15">15</a></sup> but it is normally repressed in most adult organs with the exception of germ cells and CD34+ hematopoietic stem cells.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16" href-manipulated="true" aria-label="Reference 16">16</a></sup> <i>SALL4</i> is reactivated or aberrantly expressed in a multitude of cancers and has been identified by meta-analysis as a poor prognostic factor. Mechanistically, up-regulation of SALL4 promotes proliferation, metastasis, and drug resistance of cancer cells,<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17 r18" id="body-ref-r18" href-manipulated="true">17,18</a></sup> through a number of mechanisms, such as repression of tumor-suppressor genes<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="body-ref-r19" href-manipulated="true" aria-label="Reference 19">19</a></sup> and activation of other oncogenes.<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20" id="body-ref-r20-1" href-manipulated="true" aria-label="Reference 20">20</a></sup> In hematologic cancers, <i>SALL4</i> is aberrantly expressed in high-risk myelodysplastic syndrome,<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21" id="body-ref-r21-1" href-manipulated="true" aria-label="Reference 21">21</a></sup> acute myeloid leukemia,<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11 r20" id="body-ref-r20-2" href-manipulated="true">11,20</a></sup> the blast phase of chronic myeloid leukemia,<sup><a href="#core-r22" role="doc-biblioref" data-xml-rid="r22" id="body-ref-r22" href-manipulated="true" aria-label="Reference 22">22</a></sup> and precursor B-cell lymphoblastic leukemia or lymphoma.<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23" href-manipulated="true" aria-label="Reference 23">23</a></sup> In a murine model with constitutive <i>SALL4</i> expression, mice had myelodysplastic syndrome–like features and subsequently leukemic transformation through activation of the Wnt–beta-catenin pathway.<sup><a href="#core-r24" role="doc-biblioref" data-xml-rid="r24" id="body-ref-r24" href-manipulated="true" aria-label="Reference 24">24</a></sup> Methylation is known to regulate <i>SALL4</i> expression and reactivation in solid tumors.<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25 r26" id="body-ref-r26" href-manipulated="true">25,26</a></sup> The expression of <i>SALL4</i> in hematologic cancers may also be related to its DNA methylation status. The effect of hypomethylating agents on <i>SALL4</i> expression and its clinical implications are unknown.</div><div role="paragraph">Hypomethylating agents are now being used to treat blood cancers as well as solid tumors. Because they were first approved by the Food and Drug Administration (FDA) to treat patients with myelodysplastic syndrome more than a decade ago, we therefore retrospectively analyzed <i>SALL4</i> expression and clinical survival among 68 patients with myelodysplastic syndrome in two cohorts (25 patients in cohort 1 and 43 patients in cohort 2) with bone marrow samples obtained before and after treatment with a hypomethylating agent. Myelodysplastic syndrome comprises heterogeneous myeloid disorders characterized by cytopenias and dysplasia in peripheral blood and bone marrow, with ineffective hematopoiesis and a variable risk of leukemic transformation.<sup><a href="#core-r27" role="doc-biblioref" data-xml-rid="r27 r28" id="body-ref-r28" href-manipulated="true">27,28</a></sup> To define the mechanisms of altered expression of <i>SALL4</i> in response to treatment with a hypomethylating agent, we used a CRISPR-DiR (clustered regularly interspaced short palindromic repeats–DNA methyltransferase 1 [DNMT1]–interacting RNA) approach. First, we identified and demethylated the CpG island that is critical for <i>SALL4</i> expression. We then evaluated the effects of treatment with a hypomethylating agent on the methylation status of <i>SALL4</i> in samples obtained from patients with myelodysplastic syndrome.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Patients and Sample Collection</h3><div role="paragraph">Bone marrow samples in cohort 1 were obtained from 37 patients with newly diagnosed myelodysplastic syndrome who were enrolled in the BMT-AZA trial.<sup><a href="#core-r29" role="doc-biblioref" data-xml-rid="r29 r30" id="body-ref-r30-1" href-manipulated="true">29,30</a></sup> The current study was overseen and approved by the University of Rome Tor Vergata. Written informed consent was obtained from the patients before inclusion in the study. CD34− bone marrow mononuclear cells obtained from 10 healthy donors and CD34+ cells obtained from 5 healthy donors were used as control cohorts. Of the 37 patients with myelodysplastic syndrome, 25 had paired bone marrow samples collected before and after four cycles of azacytidine. In cohort 2, a total of 43 bone marrow samples were obtained from the Institute of Hematology and Blood Diseases Hospital in Tianjin, China, before or after three to five cycles of treatment with a hypomethylating agent. Patient samples were obtained with written informed consent in accordance with the Declaration of Helsinki and approval of the human research ethics committee at the Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences. Bone marrow mononuclear cells were isolated by Ficoll gradient centrifugation with the use of Lympholyte-H (Cedarlane), in accordance with the instructions of the manufacturer. Myelodysplastic syndrome was diagnosed in accordance with the 2016 World Health Organization (WHO) classification.<sup><a href="#core-r31" role="doc-biblioref" data-xml-rid="r31" id="body-ref-r31" href-manipulated="true" aria-label="Reference 31">31</a></sup> Other clinical characteristics, including age at diagnosis, sex, Revised International Prognostic Scoring System risk status, WHO Classification-based Prognostic Scoring System risk status, response after treatment with a hypomethylating agent, peripheral-blood counts, bone marrow blast counts, and cytogenetic features, were also reviewed. The definition of first response follows the International Working Group criteria.<sup><a href="#core-r32" role="doc-biblioref" data-xml-rid="r32" id="body-ref-r32" href-manipulated="true" aria-label="Reference 32">32</a></sup> Patients who had a response included those having complete remission, partial remission, or hematologic improvement, whereas patients who did not have a response included those with stable disease or progressive disease.</div></section><section id="sec-1-2"><h3>Statistical Analysis</h3><div role="paragraph">Clinical characteristics and mutational profiling are presented as the number and percentage of patients. Data are presented as medians and interquartile ranges for skewed data. Categorical variables were compared with the use of Fisher’s exact test or the chi-square test, as appropriate, and continuous variables were compared with the use of the Wilcoxon rank-sum test. We also used the Wilcoxon rank-sum test for paired observations and factor change in <i>SALL4</i> messenger RNA (mRNA) levels in patients who had a response as compared with those who did not have a response.</div><div role="paragraph">Progression-free survival was defined as the time from treatment with a hypomethylating agent to disease progression or death from the treatment, and overall survival was defined as time from treatment with a hypomethylating agent to death. Overall and progression-free survival were analyzed with the use of the Kaplan–Meier product-limit method with censoring for patients who did not have disease progression or who did not die during the treatment period. A log-rank test was used to compare survival curves for statistical significance. Hazard ratios and 95% confidence intervals were calculated with the use of a Cox proportional-hazards model. All prognostic factors with a P value of less than 0.1 in the univariate model were further entered into the multivariate analysis.</div><div role="paragraph">All statistical testing was performed with the use of two-tailed tests; a P value of less than 0.05 was considered to indicate statistical significance. All analyses were performed with the use of SPSS statistical software, version 22 (SPSS). A droplet digital polymerase-chain-reaction (ddPCR) experiment was repeated three times for each group of experiments, and Student’s t-test was used. Additional materials are described in the <a href="#ap1">Supplementary Appendix</a>, available with the full text of this article at NEJM.org.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Hypomethylating Agents and Up-Regulation of <i>SALL4</i></h3><div role="paragraph">To evaluate the effect of hypomethylating agents on <i>SALL4</i> expression after treatment, we first measured the baseline <i>SALL4</i> expression at diagnosis in bone marrow mononuclear cells obtained from patients with myelodysplastic syndrome before azacytidine treatment in cohort 1. Levels of <i>SALL4</i> mRNA were significantly higher in 37 patients with myelodysplastic syndrome than in healthy donors (P=0.002) (Fig. S1A in the <a href="#ap1">Supplementary Appendix</a>), a finding similar to what has been reported previously.<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21" id="body-ref-r21-2" href-manipulated="true" aria-label="Reference 21">21</a></sup> In cohort 1, a total of 25 patients had available paired bone marrow samples at diagnosis and after four cycles of azacytidine. Of these 25 patients, 12 (48%) were classified as having had a response: 9 (36%) had a complete response, 2 (8%) had a partial response, and 1 (4%) had hematologic improvement. The remaining 13 patients (52%) were classified as not having had a response: 10 (40%) had stable disease, and 3 (12%) had progressive disease. Baseline <i>SALL4</i> expression at diagnosis did not differ substantially among these groups. In cohort 2, of the 43 patients, 20 (47%) were classified as having had response: 15 (35%) had a complete response, and 5 (12%) had hematologic improvement. The remaining 23 patients (53%) were classified as not having had a response: 18 (42%) had stable disease, and 5 (12%) had progressive disease.</div><div role="paragraph">These 68 patients were then stratified according to the factor change in <i>SALL4</i> mRNA expression before and after treatment with a hypomethylating agent. A waterfall plot depicting the factor changes in <i>SALL4</i> mRNA levels showed that patients can be separated into two groups, one with <i>SALL4</i> up-regulation and the other with <i>SALL4</i> down-regulation. In cohort 1, a total of 10 of the 25 patients (40%) had an increase in <i>SALL4</i> expression and 15 patients (60%) had a decrease in <i>SALL4</i> expression after four cycles of azacytidine treatment (<a href="#f1">Figure 1A</a>). The median log<sub>2</sub> factor change was 2.78 (interquartile range, 2.15 to 5.65) in patients with <i>SALL4</i> up-regulation and −2.25 (interquartile range, −1.26 to −4.45) in those with <i>SALL4</i> down-regulation. In cohort 2, a total of 13 patients (30%) had <i>SALL4</i> up-regulation and 30 patients (70%) had <i>SALL4</i> down-regulation after three to five cycles of treatment with a hypomethylating agent (<a href="#f1">Figure 1B</a>). The median log<sub>2</sub> factor change was 1.99 (interquartile range, 0.70 to 3.05) in patients with <i>SALL4</i> up-regulation and −1.99 (interquartile range, −0.84 to −2.71) in those with <i>SALL4</i> down-regulation. No significant difference in the factor change in <i>SALL4</i> mRNA was noted between patients who had a response and those who did not have a response in cohort 1 (Fig. S1B) and cohort 2 (Fig. S1C).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2119771_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2119771_f1.jpg"><img src="/cms/10.1056/NEJMoa2119771/asset/acefb654-f828-49eb-a68e-b8bb6a6aea21/assets/images/large/nejmoa2119771_f1.jpg" height="3078" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Increased <i>SALL4</i> Expression in Patients with Myelodysplastic Syndrome after Treatment with a Hypomethylating Agent.</div><div class="notes"><div role="doc-footnote">Panel A shows a waterfall plot of the log<sub>2</sub> factor change in <i>SALL4</i> expression in 25 patients after four cycles of azacytidine treatment in cohort 1. Panel B shows a waterfall plot of the log<sub>2</sub> factor change in <i>SALL4</i> expression in 43 patients after three to five cycles of treatment with a hypomethylating agent in cohort 2. The term t0 denotes before any cycles of treatment, and t4 after four cycles of treatment. Panel C shows overall survival among patients with <i>SALL4</i> up-regulation and those with <i>SALL4</i> down-regulation in cohort 1, and Panel D shows the corresponding data in cohort 2. In Panels C and D, tick marks indicate censored data. A log-rank test was used to compare survival curves for statistical significance in Panels C and D.</div></div></figcaption></figure></div><div role="paragraph">When overall survival was compared between the patients with <i>SALL4</i> up-regulation and those with <i>SALL4</i> down-regulation in both cohort 1 and cohort 2, those with <i>SALL4</i> up-regulation had poorer overall survival than those with <i>SALL4</i> down-regulation (P=0.03 in cohort 1 and P=0.04 in cohort 2) (<a href="#f1">Figure 1C and 1D</a>). These findings indicate that <i>SALL4</i> up-regulation may be associated with worse survival.</div><div role="paragraph">The demographic and clinical characteristics of the patients with <i>SALL4</i> up-regulation and those with <i>SALL4</i> down-regulation are shown in <a href="#t1">Table 1</a> and <a href="#t2">Table 2</a>. The median follow-up after the initiation of therapy was 14.1 months (interquartile range, 9.0 to 20.4) in cohort 1 and 17.0 months (interquartile range, 12.0 to 28.0) in cohort 2. We further conducted a Cox proportional-hazards model analysis of prognostic factors for overall survival on the basis of patient characteristics at diagnosis, mutational profile,<sup><a href="#core-r30" role="doc-biblioref" data-xml-rid="r30" id="body-ref-r30-2" href-manipulated="true" aria-label="Reference 30">30</a></sup> and <i>SALL4</i> expression changes. In a multivariate analysis, <i>SALL4</i> up-regulation was a common independent negative predictor of overall survival (cohort 1: hazard ratio for death, 6.48; 95% confidence interval [CI], 1.06 to 39.67; cohort 2: hazard ratio, 2.74; 95% CI, 0.93 to 8.03) (Tables S1 and S2). In addition, the presence of a <i>RUNX1</i> mutation in cohort 1 and the lack of a treatment response in cohort 2 were also negative predictors of overall survival in a multivariate analysis.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2119771_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2119771_t1.jpg"><img src="/cms/10.1056/NEJMoa2119771/asset/1a30f958-333f-4714-b22c-0353c4245a1f/assets/images/large/nejmoa2119771_t1.jpg" height="3270" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders"><i>SALL4</i> Up-Regulation<br>(N=10)</th><th class="txxr-borders"><i>SALL4</i> Down-Regulation<br>(N=15)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median age (IQR) — yr</td><td class="xxxx-borders shading">59.6 (46.2–61)</td><td class="xxxr-borders shading">59.5 (45–61.5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Sex — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Male</td><td class="xxxx-borders shading">9 (90)</td><td class="xxxr-borders shading">8 (53)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Female</td><td class="xxxx-borders">1 (10)</td><td class="xxxr-borders">7 (47)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">IPSS risk status — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Low or intermediate-1</td><td class="xxxx-borders">1 (10)</td><td class="xxxr-borders">1 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Intermediate-2 or high</td><td class="xxxx-borders shading">9 (90)</td><td class="xxxr-borders shading">13 (87)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">WPSS risk status — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Very low or low</td><td class="xxxx-borders shading">1 (10)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Intermediate</td><td class="xxxx-borders">1 (10)</td><td class="xxxr-borders">2 (13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">High or very high</td><td class="xxxx-borders shading">8 (80)</td><td class="xxxr-borders shading">10 (67)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">IPSS-R risk status — no./total no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Very low</td><td class="xxxx-borders shading">0/9</td><td class="xxxr-borders shading">1/13 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Low</td><td class="xxxx-borders">0/9</td><td class="xxxr-borders">1/13 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Intermediate</td><td class="xxxx-borders shading">2/9 (22)</td><td class="xxxr-borders shading">2/13 (15)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">High</td><td class="xxxx-borders">3/9 (33)</td><td class="xxxr-borders">2/13 (15)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Very high</td><td class="xxxx-borders shading">4/9 (44)</td><td class="xxxr-borders shading">7/13 (54)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Treatment response — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Yes</td><td class="xxxx-borders shading">5 (50)</td><td class="xxxr-borders shading">7 (47)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No</td><td class="xxxx-borders">5 (50)</td><td class="xxxr-borders">8 (53)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median white-cell count (IQR) — per mm<sup>3</sup></td><td class="xxxx-borders shading">2450 (1900–4015)</td><td class="xxxr-borders shading">3320 (2280–10,410)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median absolute neutrophil count (IQR) — per mm<sup>3</sup></td><td class="xxxx-borders">400 (215–1490)</td><td class="xxxr-borders">700 (400–2000)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median hemoglobin level (IQR) — g/dl</td><td class="xxxx-borders shading">9.9 (8.6–10.6)</td><td class="xxxr-borders shading">9.4 (8.7–11.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median platelet count (IQR) — per mm<sup>3</sup></td><td class="xxxx-borders">49,500 (26,750–164,250)</td><td class="xxxr-borders">77,000 (49,000–129,000)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median percentage of blasts in bone marrow aspirate (IQR)</td><td class="xxxx-borders shading">13 (11–15)</td><td class="xxxr-borders shading">12 (3.8–17.8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Cytogenetic features of MDS — no. (%)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Good karyotype</td><td class="xxxx-borders shading">4 (40)</td><td class="xxxr-borders shading">5 (33)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Intermediate karyotype</td><td class="xxxx-borders">2 (20)</td><td class="xxxr-borders">2 (13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Poor karyotype</td><td class="xxxx-borders shading">3 (30)</td><td class="xxxr-borders shading">6 (40)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Mutational profiling — no. (%)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>TET2</i> mutation</td><td class="xxxx-borders shading">1 (10)</td><td class="xxxr-borders shading">6 (40)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>ASXL1</i> mutation</td><td class="xxxx-borders">3 (30)</td><td class="xxxr-borders">6 (40)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>RUNX1</i> mutation</td><td class="xxxx-borders shading">2 (20)</td><td class="xxxr-borders shading">4 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>SETBP1</i> mutation</td><td class="xxxx-borders">2 (20)</td><td class="xxxr-borders">4 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>TP53</i> mutation</td><td class="xxxx-borders shading">3 (30)</td><td class="xxxr-borders shading">2 (13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>ZRSF2</i> mutation</td><td class="xxxx-borders">4 (40)</td><td class="xxxr-borders">1 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>DNMT3A</i> mutation</td><td class="xxxx-borders shading">1 (10)</td><td class="xxxr-borders shading">3 (20)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>SRSF2</i> mutation</td><td class="xxxx-borders">1 (10)</td><td class="xxxr-borders">3 (20)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>SF3B1</i> mutation</td><td class="xxxx-borders shading">1 (10)</td><td class="xxxr-borders shading">2 (13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>U2AF1</i> mutation</td><td class="xxxx-borders">3 (30)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>CEBPA</i> mutation</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">3 (20)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>CBL</i> mutation</td><td class="xxxx-borders">1 (10)</td><td class="xxxr-borders">1 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>ETV6</i> mutation</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">2 (13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>IDH2</i> mutation</td><td class="xxxx-borders">1 (10)</td><td class="xxxr-borders">1 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>NRAS</i> mutation</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">2 (13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>CSF3R</i> mutation</td><td class="xxxx-borders">1 (10)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left"><i>JAK2</i> mutation</td><td class="xbxx-borders shading">1 (10)</td><td class="xbxr-borders shading">0</td></tr></tbody></table></div><figcaption><div class="caption">Baseline Characteristics of 25 Patients Treated with a Hypomethylating Agent in Cohort 1.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">IPSS denotes International Prognostic Scoring System, IPSS-R Revised IPSS, IQR interquartile range, MDS myelodysplastic syndrome, and WPSS World Health Organization Classification-based Prognostic Scoring System.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Three patients (one with <i>SALL4</i> up-regulation and two with <i>SALL4</i> down-regulation) had no metaphase of cytogenetic analysis.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">No mutations in <i>ABL1</i>, <i>BRAF</i>, <i>CALR</i>, <i>EZH2</i>, <i>FLT3</i>, <i>HRAS</i>, <i>IDH1</i>, <i>KIT</i>, <i>KRAS</i>, <i>MPL</i>, <i>NPM1</i>, <i>PTPN11</i>, and <i>WT1</i> were observed in either group.</div></div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2119771_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2119771_t2.jpg"><img src="/cms/10.1056/NEJMoa2119771/asset/5b91d533-9cbb-4c35-9092-5180a4987c2d/assets/images/large/nejmoa2119771_t2.jpg" height="3253" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristics</th><th class="txxx-borders"><i>SALL4</i> Up-Regulation<br>(N=13)</th><th class="txxr-borders"><i>SALL4</i> Down-Regulation<br>(N=30)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median age (IQR) — yr</td><td class="xxxx-borders shading">65 (60–69)</td><td class="xxxr-borders shading">62.5 (59.8–67.5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Sex — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Male</td><td class="xxxx-borders shading">11 (85)</td><td class="xxxr-borders shading">17 (57)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Female</td><td class="xxxx-borders">2 (15)</td><td class="xxxr-borders">13 (43)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">IPSS risk status — no./total no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Low or intermediate-1</td><td class="xxxx-borders">8/11 (73)</td><td class="xxxr-borders">17/26 (65)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Intermediate-2 or high</td><td class="xxxx-borders shading">3/11 (27)</td><td class="xxxr-borders shading">9/26 (35)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">WPSS risk status — no./total no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Very low or low</td><td class="xxxx-borders shading">1/11 (9)</td><td class="xxxr-borders shading">2/26 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Intermediate</td><td class="xxxx-borders">2/11 (18)</td><td class="xxxr-borders">9/26 (35)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">High or very high</td><td class="xxxx-borders shading">8/11 (73)</td><td class="xxxr-borders shading">15/26 (58)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">IPSS-R risk status — no./total no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Very low</td><td class="xxxx-borders shading">0/13</td><td class="xxxr-borders shading">1/26 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Low</td><td class="xxxx-borders">1/13 (8)</td><td class="xxxr-borders">1/26 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Intermediate</td><td class="xxxx-borders shading">4/13 (31)</td><td class="xxxr-borders shading">7/26 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">High</td><td class="xxxx-borders">6/13 (46)</td><td class="xxxr-borders">13/26 (50)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Very high</td><td class="xxxx-borders shading">2/13 (15)</td><td class="xxxr-borders shading">4/26 (15)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Treatment response — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Yes</td><td class="xxxx-borders shading">5 (38)</td><td class="xxxr-borders shading">15 (50)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No</td><td class="xxxx-borders">8 (62)</td><td class="xxxr-borders">15 (50)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median white-cell count (IQR) — per mm<sup>3</sup></td><td class="xxxx-borders shading">2220 (1310–4310)</td><td class="xxxr-borders shading">2180 (1830–2750)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median absolute neutrophil count (IQR) — per mm<sup>3</sup></td><td class="xxxx-borders">780 (330–2240)</td><td class="xxxr-borders">900 (630–1370)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median hemoglobin level (IQR) — g/dl</td><td class="xxxx-borders shading">7.0 (6.2–10.2)</td><td class="xxxr-borders shading">8.1 (7.0–9.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median platelet count (IQR) — per mm<sup>3</sup></td><td class="xxxx-borders">47,000 (31,000–120,000)</td><td class="xxxr-borders">70,000 (38,000–107,000)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median percentage of blasts in bone marrow aspirate (IQR)</td><td class="xxxx-borders shading">6 (5.5–10.8)</td><td class="xxxr-borders shading">7.3 (5.4–11.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Cytogenetic features of MDS — no./total no. (%)<a href="#t2fn1" role="doc-noteref">*</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Good karyotype</td><td class="xxxx-borders shading">10/11 (91)</td><td class="xxxr-borders shading">22/26 (85)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Intermediate karyotype</td><td class="xxxx-borders">1/11 (9)</td><td class="xxxr-borders">0/26</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Poor karyotype</td><td class="xxxx-borders shading">0/11</td><td class="xxxr-borders shading">4/26 (15)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Mutational profiling — no./total no. (%)<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>TET2</i> mutation</td><td class="xxxx-borders shading">1/13 (8)</td><td class="xxxr-borders shading">2/28 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>ASXL1</i> mutation</td><td class="xxxx-borders">4/13 (31)</td><td class="xxxr-borders">5/28 (18)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>RUNX1</i> mutation</td><td class="xxxx-borders shading">3/13 (23)</td><td class="xxxr-borders shading">3/28 (11)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>SETBP1</i> mutation</td><td class="xxxx-borders">0/13</td><td class="xxxr-borders">2/28 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>TP53</i> mutation</td><td class="xxxx-borders shading">1/13 (8)</td><td class="xxxr-borders shading">4/28 (14)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>DNMT3A</i> mutation</td><td class="xxxx-borders">0/13</td><td class="xxxr-borders">1/28 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>SRSF2</i> mutation</td><td class="xxxx-borders shading">0/13</td><td class="xxxr-borders shading">1/28 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>SF3B1</i> mutation</td><td class="xxxx-borders">3/13 (23)</td><td class="xxxr-borders">2/28 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>U2AF1</i> mutation</td><td class="xxxx-borders shading">3/13 (23)</td><td class="xxxr-borders shading">4/28 (14)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>CEBPA</i> mutation</td><td class="xxxx-borders">0/13</td><td class="xxxr-borders">1/28 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>IDH2</i> mutation</td><td class="xxxx-borders shading">1/13 (8)</td><td class="xxxr-borders shading">0/28</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>NRAS</i> mutation</td><td class="xxxx-borders">0/13</td><td class="xxxr-borders">3/28 (11)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>JAK2</i> mutation</td><td class="xxxx-borders shading">1/13 (8)</td><td class="xxxr-borders shading">1/28 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>EZH2</i> mutation</td><td class="xxxx-borders">1/13 (8)</td><td class="xxxr-borders">1/28 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>FLT3</i> mutation</td><td class="xxxx-borders shading">1/13 (8)</td><td class="xxxr-borders shading">0/28</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>IDH1</i> mutation</td><td class="xxxx-borders">1/13 (8)</td><td class="xxxr-borders">2/28 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>KRAS</i> mutation</td><td class="xxxx-borders shading">1/13 (8)</td><td class="xxxr-borders shading">0/28</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left"><i>NPM1</i> mutation</td><td class="xbxx-borders">0/13</td><td class="xbxr-borders">2/28 (7)</td></tr></tbody></table></div><figcaption><div class="caption">Baseline Characteristics of 43 Patients Treated with a Hypomethylating Agent in Cohort 2.</div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Two patients with <i>SALL4</i> down-regulation had no metaphase of cytogenetic analysis. Inadequate Giemsa banding in cytogenetic analysis was seen for one patient with <i>SALL4</i> up-regulation and two patients with <i>SALL4</i> down-regulation.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">No mutations in <i>ABL1</i>, <i>BRAF</i>, <i>CALR</i>, <i>CBL</i>, <i>CSF3R</i>, <i>ETV6</i>, <i>KIT</i>, <i>MPL</i>, <i>PTPN11</i>, <i>WT1</i>, and <i>ZRSF2</i> were observed in either group. Two patients with <i>SALL4</i> down-regulation did not undergo next-generation sequencing.</div></div></div></figcaption></figure></div><div role="paragraph">Because somatic mutations, including epigenetic factors such as <i>DNMT3A</i>, <i>IDH1</i>, <i>IDH2</i>, and <i>TET2</i>, are common in patients with myelodysplastic syndrome,<sup><a href="#core-r33" role="doc-biblioref" data-xml-rid="r33" id="body-ref-r33" href-manipulated="true" aria-label="Reference 33">33</a></sup> we evaluated whether <i>SALL4</i> up-regulation or down-regulation in patients after treatment was related to their preexisting mutation status. Common somatic mutations in 30 genes, known to be frequently mutated in patients with myelodysplastic syndrome, are reported in Figure S3. At diagnosis, we identified at least one mutation in 22 of 25 patients (88%) in cohort 1 and in 32 of 41 patients (78%) in cohort 2. A total of 19 of 22 patients (86%) in cohort 1 and 16 of 32 patients (50%) in cohort 2 had more than one gene mutation. From these observations, it appears that <i>SALL4</i> up-regulation or down-regulation in patients after treatment with a hypomethylating agent was not related to their preexisting mutation status.</div></section><section id="sec-2-2"><h3>Demethylation of a Critical CpG Region and Up-Regulation of <i>SALL4</i></h3><div role="paragraph">We next investigated the mechanisms of <i>SALL4</i> up-regulation after treatment with a hypomethylating agent. One possibility is that such treatment can lead to demethylation of a CpG island that is critical for <i>SALL4</i> expression. The differential methylation of the <i>SALL4</i> locus has been observed in K562-induced pluripotency reprogrammed cells.<sup><a href="#core-r34" role="doc-biblioref" data-xml-rid="r34" id="body-ref-r34" href-manipulated="true" aria-label="Reference 34">34</a></sup> The major CpG island of <i>SALL4</i> is located across the 2000-bp locus, including 5′ untranslated region (5′UTR)–Exon 1–Intron 1. Within this CpG island, methylation of 5′UTR–Exon 1–Intron 1, a specific 500-bp DNA segment, was further observed to be negatively correlated with <i>SALL4</i> expression in patients with hepatocellular carcinoma and in hepatocellular-carcinoma cell lines<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25" id="body-ref-r25-2" href-manipulated="true" aria-label="Reference 25">25</a></sup> (<a href="#f2">Figure 2A</a>). We hypothesized that demethylation of this region could lead to up-regulation of <i>SALL4</i>.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2119771_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2119771_f2.jpg"><img src="/cms/10.1056/NEJMoa2119771/asset/a7bb9a86-fb5d-42f6-8b73-055102d12b4d/assets/images/large/nejmoa2119771_f2.jpg" height="3419" width="2231" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Demethylation of a Critical CpG Island and <i>SALL4</i> Expression in Leukemic Cells Treated with CRISPR-DiR.</div><div class="notes"><div role="doc-footnote">Panel A shows the CpG region within <i>SALL4</i> 5′ untranslated region (5′UTR)–Exon 1–Intron 1. Depicted at the top of the diagram are the 30 CpG residues; depicted below are the four <i>SALL4</i> exons (in blue) and introns (in purple), with the location of the 30 CpG residues in the Exon 1–Intron 1 region. The location of the target of the guide RNA for CRISPR-DiR (clustered regularly interspaced short palindromic repeats–DNA methyltransferase 1 [DNMT1]–interacting RNA) is shown below, targeting CpG number 11. The term dCas9 denotes nuclease-dead Cas9, and sgDiR single-guide DNMT1-interacting RNA. Panel B shows bisulfite sequencing after CRISPR-DiR of HL-60 cells transduced with either a nontargeting negative control guide RNA (DiR_NT) or a targeting guide RNA (DiR_SALL4), leading to demethylation, with higher methylation indicated by redder shading. Panel C shows up-regulation of <i>SALL4</i> transcript (copies per cell assessed by droplet digital polymerase-chain-reaction [ddPCR] assay) in HL-60 cells treated with CRISPR-DiR 8 days after transduction of the CRISPR-DiR. A Wilcoxon rank-sum test was used to evaluate the statistical difference in copies per cell between NT (in three patients) and sgSALL4 (in three patients). Data are shown as means, and error bars indicate the standard deviation.</div></div></figcaption></figure></div><div role="paragraph">To localize the critical CpG region responsible for regulation of <i>SALL4</i> expression and to test the causal relationship between DNA methylation of <i>SALL4</i> and RNA expression, we applied the CRISPR-DiR technique.<sup><a href="#core-r35" role="doc-biblioref" data-xml-rid="r35" id="body-ref-r35-1" href-manipulated="true" aria-label="Reference 35">35</a></sup> This approach uses induction of locus-specific demethylation by blocking DNMT1 activity<sup><a href="#core-r36" role="doc-biblioref" data-xml-rid="r36" id="body-ref-r36-1" href-manipulated="true" aria-label="Reference 36">36</a></sup> in cell lines with undetectable or low <i>SALL4</i> expression.</div><div role="paragraph">In the CRISPR-DiR method, two loops of the guide RNA that are not required for guide function have been replaced with sequences that specifically interact with and inhibit DNMT1.<sup><a href="#core-r35" role="doc-biblioref" data-xml-rid="r35 r36" id="body-ref-r36-2" href-manipulated="true">35,36</a></sup> This modified guide RNA can achieve site-specific demethylation.<sup><a href="#core-r35" role="doc-biblioref" data-xml-rid="r35" id="body-ref-r35-3" href-manipulated="true" aria-label="Reference 35">35</a></sup> We tested several site-specific guide RNAs around the major CpG island of <i>SALL4</i>, and only sgSALL4_1 (named as DiR_SALL4 here), targeting around the 5′UTR CpG 11 region, showed effective demethylation ability.<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25" id="body-ref-r25-3" href-manipulated="true" aria-label="Reference 25">25</a></sup> We further monitored the methylation of the 5′UTR CpG region in HL-60 cells (with no or low <i>SALL4</i> expression) after treatment with CRISPR-DiR (<a href="#f2">Figure 2A</a>). On transduction of HL-60 cells with DiR_SALL4, substantial demethylation changes were observed after 8 days (<a href="#f2">Figure 2B</a>) as well as increased SALL4 transcript levels (<a href="#f2">Figure 2C</a>), as compared with a control scrambled guide RNA (DiR-NT). Similar demethylation results by DiR_SALL4 were observed in other SNU387 cells expressing low or no <i>SALL4</i>, whereas CRISPR-DiRs targeting neighboring regions could not demethylate.<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25" id="body-ref-r25-4" href-manipulated="true" aria-label="Reference 25">25</a></sup> These findings show that demethylation of this region by <i>SALL4</i> locus-specific CRISPR-DiR can lead to up-regulation of <i>SALL4</i>.</div></section><section id="sec-2-3"><h3>Hypomethylating Agents and Demethylation of <i>SALL4</i></h3><div role="paragraph">We then tested whether <i>SALL4</i> could be up-regulated by hypomethylating agents. Using HL-60 cells, we first evaluated the dynamics of <i>SALL4</i> mRNA levels through a cycle of decitabine, using a dosage range of 100 to 500 nmol per liter. The number of mRNA copies per cell (assessed by means of ddPCR assay) and protein level (assessed by means of Western blot analysis) for SALL4 was measured at day 5. We noticed a dose-dependent up-regulation of <i>SALL4</i> mRNA expression at day 5 (<a href="#f3">Figure 3A and B</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 3</div><nav><a href="#f3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2119771_f3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f3" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f3" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2119771_f3.jpg"><img src="/cms/10.1056/NEJMoa2119771/asset/95f9df45-6d42-490e-bcc5-fb75c3ba00b3/assets/images/large/nejmoa2119771_f3.jpg" height="2671" width="2640" aria-labelledby="f3" loading="lazy"></a><figcaption><div class="caption">Demethylation of a Critical CpG Island and <i>SALL4</i> Expression in Leukemic Cells and Patients with Myelodysplastic Syndrome Treated with a Hypomethylating Agent.</div><div class="notes"><div role="doc-footnote">Panel A shows SALL4 copies per cell assessed by ddPCR assay in HL-60 cells treated with decitabine. A Wilcoxon rank-sum test was used to evaluate the statistical difference in copies per cell between dimethylsulfoxide (DMSO) and decitabine treatments. Data are shown as means, and error bars indicate standard deviations of three biologic replicates. Panel B shows Western blot analysis of HL-60 cells treated with decitabine. Panel C shows methylation profiling in HL-60 cells treated with vehicle alone as compared with those treated with decitabine at a dose of 250 nmol per liter. Treatment with a hypomethylating agent leads to demethylation of <i>SALL4</i> in patients with myelodysplastic syndrome. Panel D shows average methylation across <i>SALL4</i> 5′UTR CpG loci (1 through 11) in patients with myelodysplastic syndrome before any cycles of azacytidine treatment (t0) and after four cycles of such treatment (t4). Red dots indicate patients with up-regulation of <i>SALL4</i> expression after azacytidine treatments, and blue dots indicate patients with down-regulation of <i>SALL4</i> after azacytidine treatments. Methylation values at t0 were compared with methylation values at t4 in each up- and down-regulated group separately. The average difference in methylation between the two time points was calculated with the use of a Wilcoxon matched-pairs signed-rank test (one-tailed) for each up- and down-regulated group separately. Panel E shows methylation changes in six patients with <i>SALL4</i> up-regulation and nine patients with <i>SALL4</i> down-regulation at t0 and t4.</div></div></figcaption></figure></div><div role="paragraph">We next examined the methylation status of the <i>SALL4</i> 5′UTR CpG island region after decitabine treatment at a dose of 250 nmol per liter and found that this region was demethylated in HL-60 cells, in accordance with our CRISPR-DiR result (<a href="#f3">Figure 3C</a>). Similar results were also observed in another <i>SALL4</i>-low leukemic cell line, K562 (Fig. S4A, S4B, and S4C).</div><div role="paragraph">We next examined the methylation changes in bone marrow samples from patients with myelodysplastic syndrome before and after treatment with a hypomethylating agent. In six patients with <i>SALL4</i> up-regulation, we noticed decreased methylation at the critical 5′UTR CpG region (<a href="#f3">Figure 3D and 3E</a>). Conversely, we did not observe changes in the methylation at the same CpG region in nine patients with <i>SALL4</i> down-regulation after treatment with a hypomethylating agent (<a href="#f3">Figure 3D and 3E</a>).</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">Since its first approval by the FDA to treat myelodysplastic syndrome in 2004, hypomethylating-agent therapy has been used in patients with hematologic cancers and solid tumors. In this study, we were interested in investigating whether hypomethylating agents could activate oncogenes as an unintended consequence. We used myelodysplastic syndrome as the disease model to test our hypothesis because of the long-standing use of hypomethylating-agent therapy in this patient population and because <i>SALL4</i> has been shown to act as an oncogene in experimental animal models of myelodysplastic syndrome and acute myeloid leukemia. Although continuous hypomethylating-agent therapy in patients with myelodysplastic syndrome who had a response could improve their clinical characteristics, overall survival after such therapy in a “real-world” evaluation of patients with high-risk myelodysplastic syndrome or low-blast-count acute myeloid leukemia was lower than that expected in clinical trials,<sup><a href="#core-r37" role="doc-biblioref" data-xml-rid="r37" id="body-ref-r37" href-manipulated="true" aria-label="Reference 37">37</a></sup> and the average prognosis after failure of a hypomethylating agent was less than 6 months.<sup><a href="#core-r38" role="doc-biblioref" data-xml-rid="r38" id="body-ref-r38" href-manipulated="true" aria-label="Reference 38">38</a></sup> The mechanisms for primary and secondary drug resistance to hypomethylating agents and associated prognostic factors are still under active investigation.</div><div role="paragraph">In our two cohorts of patients with myelodysplastic syndrome from distinct ethnic backgrounds, we observed that after treatment with a hypomethylating agent, 23 of 68 patients (34%) had <i>SALL4</i> up-regulation and 45 (66%) had <i>SALL4</i> down-regulation. We observed that a poor long-term outcome correlates with <i>SALL4</i> up-regulation. The important role of SALL4 in myelodysplastic syndrome and acute myeloid leukemia has been shown in previous studies.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11-3" href-manipulated="true" aria-label="Reference 11">11</a></sup> In SALL4 transgenic (Tg) mice, ineffective hematopoiesis and myelodysplastic syndrome–like features were observed: increased apoptosis with decreased complete blood-cell counts and abnormal morphologic features of blood cells. Impairment of DNA-damage repair was also noted in these Tg mice. Therefore, we hypothesize that up-regulation of SALL4 can lead to defective hematopoiesis, accumulation of mutations, and progression to acute myeloid leukemia, which may in part explain the poorer prognosis in patients with myelodysplastic syndrome and <i>SALL4</i> up-regulation. Identifying other oncogenes that are similarly activated by hypomethylating-agent therapy and evaluation of these and <i>SALL4</i> expression in larger prospective trial samples in the future will be necessary to validate this notion.</div><div role="paragraph">Another unique aspect of <i>SALL4</i> is that its expression is associated with DNA methylation status. Previously, a major challenge in the field of DNA methylation was to show a causal relationship between the DNA methylation and gene expression at a locus-specific and cellular level. Recent advances in functional genomic approaches such as the use of the CRISPR–Cas9 nuclease system have provided us with additional tools to address this question. Using the locus-specific CRISPR-DiR approach, we have identified a critical CpG island responsible for <i>SALL4</i> expression and, more importantly, shown that treatment with a hypomethylating agent leads to demethylation of this region and up-regulation of <i>SALL4</i>. Demethylation of this same region was observed in patients with myelodysplastic syndrome having increased <i>SALL4</i> expression after hypomethylating-agent therapy. These observations support our hypothesis that treatment with a hypomethylating agent can up-regulate oncogenes such as <i>SALL4</i>.</div><div role="paragraph">It is unclear why only a subgroup of patients had up-regulation of <i>SALL4</i> after treatment with a hypomethylating agent, and future studies will be necessary to fully understand the mechanism or mechanisms. It is possible that DNA demethylation is the first step for gene activation, and additional chromatin remodeling and interaction between enhancer and promoter are needed to maintain gene expression. For example, in a recent study, we found that demethylation and subsequent binding of methylation-sensitive regulators could lead to long-range interactions between gene locus and distal regulatory elements, resulting in sustained up-regulation of gene expression.<sup><a href="#core-r35" role="doc-biblioref" data-xml-rid="r35" id="body-ref-r35-4" href-manipulated="true" aria-label="Reference 35">35</a></sup></div><div role="paragraph">Using patient samples and a targeted demethylation assay, we found that monotherapy with a hypomethylating agent can activate or up-regulate oncogenes such as <i>SALL4</i>. Up-regulation of <i>SALL4</i> probably influences the clinical progression of the disease; similar biologic effects may accompany treatment with a hypomethylating agent in patients with cancers other than myelodysplastic syndrome. Although the up-regulation of <i>SALL4</i> may be associated with a worse prognosis, it may also provide an additional treatment option on the basis of <i>SALL4</i>-mediated cancer vulnerability. We are currently exploring the concept that if <i>SALL4</i> expression is up-regulated, a concomitant targeted therapy that directly or indirectly mitigates <i>SALL4</i> expression, function, or both could be added to the treatment plan.<sup><a href="#core-r39" role="doc-biblioref" data-xml-rid="r39" id="body-ref-r39" href-manipulated="true" aria-label="Reference 39">39</a></sup></div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div role="paragraph">Supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC) 5×1000 <span class="named-content" data-type="funder">MYNERVA</span> (Myeloid Neoplasms Research Venture AIRC) project, #21267 (<a href="http://www.progettoagimm.it" target="_blank">http://www.progettoagimm.it</a>); a grant (Finalizzata 2018: NET-2018-12365935, to Dr. Voso) from Ministero della Salute, Italy; a Singapore Translational Research Investigator Award (MOH-STaR18nov-0002, MOH-000278, to Dr. Tenen) from the <span class="named-content" data-type="funder">Singapore Ministry of Health National Medical Research Council</span>; the Singapore Ministry of Education under its Research Centers of Excellence initiative; a grant (R35CA197697, to Dr. Tenen) from the <span class="named-content" data-type="funder">National Cancer Institute, National Institutes of Health</span>; a grant (P01HL131477, to Dr. Tenen) from the <span class="named-content" data-type="funder">National Heart, Lung, and Blood Institute, National Institutes of Health</span>; a grant (to Dr. Chai) from the Xiu Research Fund; grants (APP1024364, APP1043934, and APP1102589, to Dr. Pimanda, and APP1163815, to Dr. Unnikrishnan) from the <span class="named-content" data-type="funder">National Health and Medical Research Council of Australia</span>; a Translational Program Grant (6589-210, to Dr. Unnikrishnan) from the <span class="named-content" data-type="funder">Leukemia and Lymphoma Society</span>; a grant (109-2314-B-075-078, to Dr. Y.-C. Liu) from the <span class="named-content" data-type="funder">Ministry of Science and Technology, Taiwan</span>; a grant (to Dr. Y.-C. Liu) from the Chong Hin Loon Memorial Cancer and Biotherapy Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan; a grant (81870104, to Dr. Xiao) from the <span class="named-content" data-type="funder">National Natural Science Funds, China</span>; a grant (2020-I2M-C&amp;T-A-020, to Dr. Xiao) from the <span class="named-content" data-type="funder">Chinese Academy of Medical Sciences Initiative Fund for Medical Sciences</span>; and a grant (2017RKWNJT, to Dr. Follo) from the <span class="named-content" data-type="funder">Italian Ministry of University and Research–Projects of National Relevance</span>.</div><div role="paragraph"><a href="#ap2">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2119771_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2119771/suppl_file/nejmoa2119771_appendix.pdf" download="nejmoa2119771_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2119771_appendix.pdf" data-doi="10.1056/NEJMoa2119771">Download</a></li><li>883.41 KB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2119771_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2119771/suppl_file/nejmoa2119771_disclosures.pdf" download="nejmoa2119771_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2119771_disclosures.pdf" data-doi="10.1056/NEJMoa2119771">Download</a></li><li>700.70 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Taylor SM, Jones PA. Mechanism of action of eukaryotic DNA methyltransferase: use of 5-azacytosine-containing DNA. <em>J Mol Biol</em> 1982;162:679-692.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/0022-2836(82)90395-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/6187927/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1982PV78800010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Mechanism+of+action+of+eukaryotic+DNA+methyltransferase%3A+use+of+5-azacytosine-containing+DNA.&amp;publication_year=1982&amp;journal=J+Mol+Biol&amp;pages=679-692&amp;doi=10.1016%2F0022-2836%2882%2990395-3&amp;pmid=6187927" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Leonhardt H, Page AW, Weier HU, Bestor TH. A targeting sequence directs DNA methyltransferase to sites of DNA replication in mammalian nuclei. <em>Cell</em> 1992;71:865-873.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/0092-8674(92)90561-P" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/1423634/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1992JZ63300015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+targeting+sequence+directs+DNA+methyltransferase+to+sites+of+DNA+replication+in+mammalian+nuclei.&amp;publication_year=1992&amp;journal=Cell&amp;pages=865-873&amp;doi=10.1016%2F0092-8674%2892%2990561-P&amp;pmid=1423634" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Patel K, Dickson J, Din S, Macleod K, Jodrell D, Ramsahoye B. Targeting of 5-aza-2′-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. <em>Nucleic Acids Res</em> 2010;38:4313-4324.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/nar/gkq187" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20348135/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000280538600018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+of+5-aza-2%E2%80%B2-deoxycytidine+residues+by+chromatin-associated+DNMT1+induces+proteasomal+degradation+of+the+free+enzyme.&amp;publication_year=2010&amp;journal=Nucleic+Acids+Res&amp;pages=4313-4324&amp;doi=10.1093%2Fnar%2Fgkq187&amp;pmid=20348135" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Ghoshal K, Datta J, Majumder S, et al. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. <em>Mol Cell Biol</em> 2005;25:4727-4741.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/MCB.25.11.4727-4741.2005" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15899874/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000229275000035" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=5-Aza-deoxycytidine+induces+selective+degradation+of+DNA+methyltransferase+1+by+a+proteasomal+pathway+that+requires+the+KEN+box%2C+bromo-adjacent+homology+domain%2C+and+nuclear+localization+signal.&amp;publication_year=2005&amp;journal=Mol+Cell+Biol&amp;pages=4727-4741&amp;doi=10.1128%2FMCB.25.11.4727-4741.2005&amp;pmid=15899874" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Bender CM, Zingg JM, Jones PA. DNA methylation as a target for drug design. <em>Pharm Res</em> 1998;15:175-187.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1023/A:1011946030404" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/9523301/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000072331300004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=DNA+methylation+as+a+target+for+drug+design.&amp;publication_year=1998&amp;journal=Pharm+Res&amp;pages=175-187&amp;doi=10.1023%2FA%3A1011946030404&amp;pmid=9523301" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Jüttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. <em>Proc Natl Acad Sci U S A</em> 1994;91:11797-11801.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1073/pnas.91.25.11797" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/7527544/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1994PW70800007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Toxicity+of+5-aza-2%E2%80%B2-deoxycytidine+to+mammalian+cells+is+mediated+primarily+by+covalent+trapping+of+DNA+methyltransferase+rather+than+DNA+demethylation.&amp;publication_year=1994&amp;journal=Proc+Natl+Acad+Sci+U+S+A&amp;pages=11797-11801&amp;doi=10.1073%2Fpnas.91.25.11797&amp;pmid=7527544" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD. DNA methylation inhibitor 5-Aza-2′-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. <em>Mol Cell Biol</em> 2008;28:752-771.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/MCB.01799-07" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17991895/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000252283300020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=DNA+methylation+inhibitor+5-Aza-2%E2%80%B2-deoxycytidine+induces+reversible+genome-wide+DNA+damage+that+is+distinctly+influenced+by+DNA+methyltransferases+1+and+3B.&amp;publication_year=2008&amp;journal=Mol+Cell+Biol&amp;pages=752-771&amp;doi=10.1128%2FMCB.01799-07&amp;pmid=17991895" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Li H, Chiappinelli KB, Guzzetta AA, et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. <em>Oncotarget</em> 2014;5:587-598.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.18632/oncotarget.1782" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24583822/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Immune+regulation+by+low+doses+of+the+DNA+methyltransferase+inhibitor+5-azacitidine+in+common+human+epithelial+cancers.&amp;publication_year=2014&amp;journal=Oncotarget&amp;pages=587-598&amp;doi=10.18632%2Foncotarget.1782&amp;pmid=24583822" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Fabre C, Grosjean J, Tailler M, et al. A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts. <em>Cell Cycle</em> 2008;7:2139-2145.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4161/cc.7.14.6268" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18641459/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000258829700012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+novel+effect+of+DNA+methyltransferase+and+histone+deacetylase+inhibitors%3A+NFkappaB+inhibition+in+malignant+myeloblasts.&amp;publication_year=2008&amp;journal=Cell+Cycle&amp;pages=2139-2145&amp;doi=10.4161%2Fcc.7.14.6268&amp;pmid=18641459" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Chiappinelli KB, Strissel PL, Desrichard A, et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. <em>Cell</em> 2015;162:974-986.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cell.2015.07.011" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26317466/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000360589900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inhibiting+DNA+methylation+causes+an+interferon+response+in+cancer+via+dsRNA+including+endogenous+retroviruses.&amp;publication_year=2015&amp;journal=Cell&amp;pages=974-986&amp;doi=10.1016%2Fj.cell.2015.07.011&amp;pmid=26317466" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Ma Y, Cui W, Yang J, et al. SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. <em>Blood</em> 2006;108:2726-2735.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2006-02-001594" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16763212/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000241131700041" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SALL4%2C+a+novel+oncogene%2C+is+constitutively+expressed+in+human+acute+myeloid+leukemia+%28AML%29+and+induces+AML+in+transgenic+mice.&amp;publication_year=2006&amp;journal=Blood&amp;pages=2726-2735&amp;doi=10.1182%2Fblood-2006-02-001594&amp;pmid=16763212" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r11-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and acute myeloid leukemia leukemogenesis </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] acute myeloid leukemia, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] has been shown in previous studies. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Kobayashi D, Kuribayashi K, Tanaka M, Watanabe N. Overexpression of SALL4 in lung cancer and its importance in cell proliferation. <em>Oncol Rep</em> 2011;26:965-970.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21725617/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000294381100027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Overexpression+of+SALL4+in+lung+cancer+and+its+importance+in+cell+proliferation.&amp;publication_year=2011&amp;journal=Oncol+Rep&amp;pages=965-970&amp;pmid=21725617" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Yong KJ, Li A, Ou W-B, et al. Targeting SALL4 by entinostat in lung cancer. <em>Oncotarget</em> 2016;7:75425-75440.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.18632/oncotarget.12251" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27705911/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+SALL4+by+entinostat+in+lung+cancer.&amp;publication_year=2016&amp;journal=Oncotarget&amp;pages=75425-75440&amp;doi=10.18632%2Foncotarget.12251&amp;pmid=27705911" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Yong KJ, Gao C, Lim JSJ, et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. <em>N Engl J Med</em> 2013;368:2266-2276.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_3_15_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2119771&amp;key=10.1056%2FNEJMoa1300297&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23758232/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000320230500002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Oncofetal+gene+SALL4+in+aggressive+hepatocellular+carcinoma.&amp;publication_year=2013&amp;journal=N+Engl+J+Med&amp;pages=2266-2276&amp;doi=10.1056%2FNEJMoa1300297&amp;pmid=23758232" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Elling U, Klasen C, Eisenberger T, Anlag K, Treier M. Murine inner cell mass-derived lineages depend on Sall4 function. <em>Proc Natl Acad Sci U S A</em> 2006;103:16319-16324.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1073/pnas.0607884103" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17060609/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000241879500047" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Murine+inner+cell+mass-derived+lineages+depend+on+Sall4+function.&amp;publication_year=2006&amp;journal=Proc+Natl+Acad+Sci+U+S+A&amp;pages=16319-16324&amp;doi=10.1073%2Fpnas.0607884103&amp;pmid=17060609" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Gao C, Kong NR, Li A, et al. SALL4 is a key transcription regulator in normal human hematopoiesis. <em>Transfusion</em> 2013;53:1037-1049.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1537-2995.2012.03888.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22934838/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000318657200016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SALL4+is+a+key+transcription+regulator+in+normal+human+hematopoiesis.&amp;publication_year=2013&amp;journal=Transfusion&amp;pages=1037-1049&amp;doi=10.1111%2Fj.1537-2995.2012.03888.x&amp;pmid=22934838" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Zhang L, Xu Z, Xu X, et al. SALL4, a novel marker for human gastric carcinogenesis and metastasis. <em>Oncogene</em> 2014;33:5491-5500.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/onc.2013.495" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24276240/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000346087900002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SALL4%2C+a+novel+marker+for+human+gastric+carcinogenesis+and+metastasis.&amp;publication_year=2014&amp;journal=Oncogene&amp;pages=5491-5500&amp;doi=10.1038%2Fonc.2013.495&amp;pmid=24276240" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Gao C, Dimitrov T, Yong KJ, et al. Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex. <em>Blood</em> 2013;121:1413-1421.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2012-04-424275" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23287862/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000321750000026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+transcription+factor+SALL4+in+acute+myeloid+leukemia+by+interrupting+its+interaction+with+an+epigenetic+complex.&amp;publication_year=2013&amp;journal=Blood&amp;pages=1413-1421&amp;doi=10.1182%2Fblood-2012-04-424275&amp;pmid=23287862" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Lu J, Jeong H-W, Kong N, et al. Stem cell factor SALL4 represses the transcriptions of PTEN and SALL1 through an epigenetic repressor complex. <em>PLoS One</em> 2009;4(5):e5577-e5577.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0005577" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19440552/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000266107500008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Stem+cell+factor+SALL4+represses+the+transcriptions+of+PTEN+and+SALL1+through+an+epigenetic+repressor+complex.&amp;publication_year=2009&amp;journal=PLoS+One&amp;pages=e5577-e5577&amp;doi=10.1371%2Fjournal.pone.0005577&amp;pmid=19440552" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Li A, Yang Y, Gao C, et al. A SALL4/MLL/HOXA9 pathway in murine and human myeloid leukemogenesis. <em>J Clin Invest</em> 2013;123:4195-4207.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r20" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI62891" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24051379/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000325443100016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+SALL4%2FMLL%2FHOXA9+pathway+in+murine+and+human+myeloid+leukemogenesis.&amp;publication_year=2013&amp;journal=J+Clin+Invest&amp;pages=4195-4207&amp;doi=10.1172%2FJCI62891&amp;pmid=24051379" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r20" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r20-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and activation of other oncogenes. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] acute myeloid leukemia, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Wang F, Guo Y, Chen Q, et al. Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes. <em>J Hematol Oncol</em> 2013;6:73-73.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r21" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/1756-8722-6-73" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24283704/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000325533300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Stem+cell+factor+SALL4%2C+a+potential+prognostic+marker+for+myelodysplastic+syndromes.&amp;publication_year=2013&amp;journal=J+Hematol+Oncol&amp;pages=73-73&amp;doi=10.1186%2F1756-8722-6-73&amp;pmid=24283704" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r21" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in high-risk myelodysplastic syndrome, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] to what has been reported previously. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Lu J, Ma Y, Kong N, et al. Dissecting the role of SALL4, a newly identified stem cell factor, in chronic myelogenous leukemia. <em>Leukemia</em> 2011;25:1211-1213.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/leu.2011.65" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21468036/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000292682600024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dissecting+the+role+of+SALL4%2C+a+newly+identified+stem+cell+factor%2C+in+chronic+myelogenous+leukemia.&amp;publication_year=2011&amp;journal=Leukemia&amp;pages=1211-1213&amp;doi=10.1038%2Fleu.2011.65&amp;pmid=21468036" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Cui W, Kong NR, Ma Y, Amin HM, Lai R, Chai L. Differential expression of the novel oncogene, SALL4, in lymphoma, plasma cell myeloma, and acute lymphoblastic leukemia. <em>Mod Pathol</em> 2006;19:1585-1592.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/modpathol.3800694" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16998462/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000242237700009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Differential+expression+of+the+novel+oncogene%2C+SALL4%2C+in+lymphoma%2C+plasma+cell+myeloma%2C+and+acute+lymphoblastic+leukemia.&amp;publication_year=2006&amp;journal=Mod+Pathol&amp;pages=1585-1592&amp;doi=10.1038%2Fmodpathol.3800694&amp;pmid=16998462" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Shuai X, Zhou D, Shen T, et al. Overexpression of the novel oncogene SALL4 and activation of the Wnt/beta-catenin pathway in myelodysplastic syndromes. <em>Cancer Genet Cytogenet</em> 2009;194:119-124.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cancergencyto.2009.06.006" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19781444/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000270585200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Overexpression+of+the+novel+oncogene+SALL4+and+activation+of+the+Wnt%2Fbeta-catenin+pathway+in+myelodysplastic+syndromes.&amp;publication_year=2009&amp;journal=Cancer+Genet+Cytogenet&amp;pages=119-124&amp;doi=10.1016%2Fj.cancergencyto.2009.06.006&amp;pmid=19781444" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Kwon J, Liu YV, Gao C, et al. Pseudogene-mediated DNA demethylation leads to oncogene activation. <em>Sci Adv</em> 2021;7(40):eabg1695-eabg1695.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r25" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/sciadv.abg1695" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34597139/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000703091100003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pseudogene-mediated+DNA+demethylation+leads+to+oncogene+activation.&amp;publication_year=2021&amp;journal=Sci+Adv&amp;pages=eabg1695-eabg1695&amp;doi=10.1126%2Fsciadv.abg1695&amp;pmid=34597139" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r25" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r26" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and reactivation in solid tumors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r25-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and in hepatocellular-carcinoma cell lines </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r25-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] showed effective demethylation ability. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r25-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] neighboring regions could not demethylate. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Fan H, Cui Z, Zhang H, et al. DNA demethylation induces SALL4 gene re-expression in subgroups of hepatocellular carcinoma associated with Hepatitis B or C virus infection. <em>Oncogene</em> 2017;36:2435-2445.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/onc.2016.399" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27797380/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000400268900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=DNA+demethylation+induces+SALL4+gene+re-expression+in+subgroups+of+hepatocellular+carcinoma+associated+with+Hepatitis+B+or+C+virus+infection.&amp;publication_year=2017&amp;journal=Oncogene&amp;pages=2435-2445&amp;doi=10.1038%2Fonc.2016.399&amp;pmid=27797380" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Cazzola M, Malcovati L. Myelodysplastic syndromes — coping with ineffective hematopoiesis. <em>N Engl J Med</em> 2005;352:536-538.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_3_28_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2119771&amp;key=10.1056%2FNEJMp048266&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15703418/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000226862100003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Myelodysplastic+syndromes+%E2%80%94+coping+with+ineffective+hematopoiesis.&amp;publication_year=2005&amp;journal=N+Engl+J+Med&amp;pages=536-538&amp;doi=10.1056%2FNEJMp048266&amp;pmid=15703418" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. <em>Blood</em> 2015;126:9-16.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2015-03-631747" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25931582/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000357696200006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clonal+hematopoiesis+of+indeterminate+potential+and+its+distinction+from+myelodysplastic+syndromes.&amp;publication_year=2015&amp;journal=Blood&amp;pages=9-16&amp;doi=10.1182%2Fblood-2015-03-631747&amp;pmid=25931582" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Voso MT, Leone G, Piciocchi A, et al. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. <em>Ann Oncol</em> 2017;28:1547-1553.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdx154" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28368509/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000404134100021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Feasibility+of+allogeneic+stem-cell+transplantation+after+azacitidine+bridge+in+higher-risk+myelodysplastic+syndromes+and+low+blast+count+acute+myeloid+leukemia%3A+results+of+the+BMT-AZA+prospective+study.&amp;publication_year=2017&amp;journal=Ann+Oncol&amp;pages=1547-1553&amp;doi=10.1093%2Fannonc%2Fmdx154&amp;pmid=28368509" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="r30" class="citations"><div class="citation"><div class="citation-content">Falconi G, Fabiani E, Piciocchi A, et al. Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes. <em>Leukemia</em> 2019;33:785-790.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r30" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41375-018-0284-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30291338/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000460406600023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Somatic+mutations+as+markers+of+outcome+after+azacitidine+and+allogeneic+stem+cell+transplantation+in+higher-risk+myelodysplastic+syndromes.&amp;publication_year=2019&amp;journal=Leukemia&amp;pages=785-790&amp;doi=10.1038%2Fs41375-018-0284-9&amp;pmid=30291338" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r30" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r30-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] who were enrolled in the BMT-AZA trial. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r30-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] at diagnosis, mutational profile, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="r31" class="citations"><div class="citation"><div class="citation-content">Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. <em>Blood</em> 2016;127:2391-2405.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2016-03-643544" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27069254/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000378333900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+2016+revision+to+the+World+Health+Organization+classification+of+myeloid+neoplasms+and+acute+leukemia.&amp;publication_year=2016&amp;journal=Blood&amp;pages=2391-2405&amp;doi=10.1182%2Fblood-2016-03-643544&amp;pmid=27069254" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="r32" class="citations"><div class="citation"><div class="citation-content">Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. <em>Blood</em> 2006;108:419-425.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2005-10-4149" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16609072/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000239129500012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+application+and+proposal+for+modification+of+the+International+Working+Group+%28IWG%29+response+criteria+in+myelodysplasia.&amp;publication_year=2006&amp;journal=Blood&amp;pages=419-425&amp;doi=10.1182%2Fblood-2005-10-4149&amp;pmid=16609072" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="r33" class="citations"><div class="citation"><div class="citation-content">Bejar R. Implications of molecular genetic diversity in myelodysplastic syndromes. <em>Curr Opin Hematol</em> 2017;24:73-78.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/MOH.0000000000000313" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27875374/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000393966100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Implications+of+molecular+genetic+diversity+in+myelodysplastic+syndromes.&amp;publication_year=2017&amp;journal=Curr+Opin+Hematol&amp;pages=73-78&amp;doi=10.1097%2FMOH.0000000000000313&amp;pmid=27875374" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="r34" class="citations"><div class="citation"><div class="citation-content">Tatetsu H, Kong NR, Chong G, Amabile G, Tenen DG, Chai L. SALL4, the missing link between stem cells, development and cancer. <em>Gene</em> 2016;584:111-119.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r34"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.gene.2016.02.019" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26892498/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000374602700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SALL4%2C+the+missing+link+between+stem+cells%2C+development+and+cancer.&amp;publication_year=2016&amp;journal=Gene&amp;pages=111-119&amp;doi=10.1016%2Fj.gene.2016.02.019&amp;pmid=26892498" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="r35" class="citations"><div class="citation"><div class="citation-content">Liu YV, Bassal MA, Jayasinghe MK, et al. Targeted intragenic demethylation initiates chromatin rewiring for gene activation. October 31, 2021 (<a href="https://www.biorxiv.org/content/10.1101/2020.07.16.205922v2">https://www.biorxiv.org/content/10.1101/2020.07.16.205922v2</a>). preprint.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r35" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeted+intragenic+demethylation+initiates+chromatin+rewiring+for+gene+activation.&amp;publication_year=2021" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r35" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r35-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] we applied the CRISPR-DiR technique. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r36-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] interact with and inhibit DNMT1. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r35-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] can achieve site-specific demethylation. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r35-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] sustained up-regulation of gene expression. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="r36" class="citations"><div class="citation"><div class="citation-content">Di Ruscio A, Ebralidze AK, Benoukraf T, et al. DNMT1-interacting RNAs block gene-specific DNA methylation. <em>Nature</em> 2013;503:371-376.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r36" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature12598" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24107992/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000327163200035" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=DNMT1-interacting+RNAs+block+gene-specific+DNA+methylation.&amp;publication_year=2013&amp;journal=Nature&amp;pages=371-376&amp;doi=10.1038%2Fnature12598&amp;pmid=24107992" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r36" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r36-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] demethylation by blocking DNMT1 activity </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r36-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] interact with and inhibit DNMT1. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">37.</div><div id="r37" class="citations"><div class="citation"><div class="citation-content">Mozessohn L, Cheung MC, Fallahpour S, et al. Azacitidine in the ‘real-world’: an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada. <em>Br J Haematol</em> 2018;181:803-815.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r37"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjh.15273" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29767427/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000435268600011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Azacitidine+in+the+%E2%80%98real-world%E2%80%99%3A+an+evaluation+of+1101+higher-risk+myelodysplastic+syndrome%2Flow+blast+count+acute+myeloid+leukaemia+patients+in+Ontario%2C+Canada.&amp;publication_year=2018&amp;journal=Br+J+Haematol&amp;pages=803-815&amp;doi=10.1111%2Fbjh.15273&amp;pmid=29767427" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">38.</div><div id="r38" class="citations"><div class="citation"><div class="citation-content">Prébet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. <em>J Clin Oncol</em> 2011;29:3322-3327.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2011.35.8135" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21788559/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000294008500027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Outcome+of+high-risk+myelodysplastic+syndrome+after+azacitidine+treatment+failure.&amp;publication_year=2011&amp;journal=J+Clin+Oncol&amp;pages=3322-3327&amp;doi=10.1200%2FJCO.2011.35.8135&amp;pmid=21788559" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">39.</div><div id="r39" class="citations"><div class="citation"><div class="citation-content">Yang J, Gao C, Liu M, et al. Targeting an inducible SALL4-mediated cancer vulnerability with sequential therapy. <em>Cancer Res</em> 2021;81:6018-6028.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/0008-5472.CAN-21-0030" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34593523/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000726534400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+an+inducible+SALL4-mediated+cancer+vulnerability+with+sequential+therapy.&amp;publication_year=2021&amp;journal=Cancer+Res&amp;pages=6018-6028&amp;doi=10.1158%2F0008-5472.CAN-21-0030&amp;pmid=34593523" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/386/21"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">386</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">21</span></span> • <span property="datePublished">May 26, 2022</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">1998</span>-<span property="pageEnd">2010</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2022 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYoa2119771" class="core-component-translation"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="https://nejmqianyan.cn/article/YXQYoa2119771?sg=AbW1N">Chinese Translation 中文翻译</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: May 25, 2022</div><div><b class="core-label">Published in issue</b>: May 26, 2022</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/anemia" alt="View article keyword Anemia" data-interactiontype="article_recirculation_click">Anemia</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/cancer" alt="View article keyword Cancer" data-interactiontype="article_recirculation_click">Cancer</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/genetics-general" alt="View article keyword Genetics General" data-interactiontype="article_recirculation_click">Genetics General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/leukemia-lymphoma" alt="View article keyword Leukemia/Lymphoma" data-interactiontype="article_recirculation_click">Leukemia/Lymphoma</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/treatments-in-oncology" alt="View article keyword Treatments in Oncology" data-interactiontype="article_recirculation_click">Treatments in Oncology</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Yao-Chung</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Junsu</span> <span property="familyName">Kwon</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Emiliano</span> <span property="familyName">Fabiani</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Zhijian</span> <span property="familyName">Xiao</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Yanjing V.</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Matilde Y.</span> <span property="familyName">Follo</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jinqin</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Huijun</span> <span property="familyName">Huang</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Chong</span> <span property="familyName">Gao</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jun</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Giulia</span> <span property="familyName">Falconi</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Lia</span> <span property="familyName">Valentini</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Carmelo</span> <span property="familyName">Gurnari</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-6829-5544" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-6829-5544</a></span>, <span property="author" typeof="Person"><span property="givenName">Carlo</span> <span property="familyName">Finelli</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Lucio</span> <span property="familyName">Cocco</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jin-Hwang</span> <span property="familyName">Liu</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Adrianna I.</span> <span property="familyName">Jones</span>, <span property="honorificSuffix">B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Junyu</span> <span property="familyName">Yang</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Henry</span> <span property="familyName">Yang</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Julie A.I.</span> <span property="familyName">Thoms</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ashwin</span> <span property="familyName">Unnikrishnan</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">John E.</span> <span property="familyName">Pimanda</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Rongqing</span> <span property="familyName">Pan</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mahmoud A.</span> <span property="familyName">Bassal</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Maria T.</span> <span property="familyName">Voso</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Daniel G.</span> <span property="familyName">Tenen</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-6423-3888" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-6423-3888</a></span>, and <span property="author" typeof="Person"><span property="givenName">Li</span> <span property="familyName">Chai</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-1937-4750" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-1937-4750</a></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Department of Pathology, Brigham and Women’s Hospital (Y.-C.L., C. Gao, Jun Liu, J.Y., L. Chai), Harvard Stem Cell Institute, Harvard Medical School (A.I.J., M.A.B., D.G.T.), and the Department of Medical Oncology, Dana–Farber Cancer Institute (R.P.) — all in Boston; the Division of Hematology, Department of Medicine, Taipei Veterans General Hospital (Y.-C.L.), and the Faculty of Medicine and the Program in Molecular Medicine, Institute of Biopharmaceutical Sciences, School of Life Science, National Yang Ming Chiao Tung University (Y.-C.L., J.-H.L.) — both in Taipei, Taiwan; the Cancer Science Institute of Singapore, Singapore (J.K., Y.V.L., H.Y., M.A.B., D.G.T.); the Department of Biomedicine and Prevention, University of Rome Tor Vergata (E.F., G.F., L.V., C. Gurnari, M.T.V.), and UniCamillus–Saint Camillus International University of Health Sciences (E.F.), Rome, and Cellular Signaling Laboratory, Department of Biomedical and Neuromotor Sciences, University of Bologna (M.Y.F., L. Cocco), and IRCCS Azienda Ospedaliero–Universitaria di Bologna, Istituto di Ematologia “Seràgnoli” (C.F.), Bologna — all in Italy; the National Clinical Research Center for Blood Diseases and State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (Z.X., Jinqin Liu, H.H.); and the School of Medical Sciences and Lowy Cancer Research Centre (J.A.I.T., J.E.P.) and Prince of Wales Clinical School and Lowy Cancer Research Centre (A.U., J.E.P.), Faculty of Medicine, University of New South Wales, Sydney, and the Department of Hematology, Prince of Wales Hospital, Randwick, NSW (J.E.P.) — both in Australia.</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Dr. Tenen can be contacted at <a href="mailto:daniel.tenen@nus.edu.sg">daniel.tenen@nus.edu.sg</a> or at the Center for Life Science, 3 Blackfan Circle, Rm. 437, Boston, MA 02115. Dr. Chai can be contacted at <a href="mailto:lchai@bwh.harvard.edu">lchai@bwh.harvard.edu</a> or at the Department of Pathology–NRB652D, Brigham and Women’s Hospital, 77 Ave. Louis Pasteur, Boston, MA 02115. Dr. Voso can be contacted at <a href="mailto:voso@med.uniroma2.it">voso@med.uniroma2.it</a> or at the Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, Rome 00133, Italy.</div><div role="doc-footnote"><div id="fn1" role="paragraph">Drs. Y.-C. Liu, Kwon, Fabiani, and Xiao contributed equally to this article.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">37</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2119771" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="730aee4c-f910-79d5-6cb8-883f5e80e10d"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=128869677" style="display:inline-block;">
                <img alt="Article has an altmetric score of 151" src="https://badges.altmetric.com/?size=320&amp;score=151&amp;types=mbrttttf" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=128869677">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_730aee4c-f910-79d5-6cb8-883f5e80e10d" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=128869677&amp;tab=news">
          Picked up by <b>17</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=128869677&amp;tab=blogs">
          Blogged by <b>1</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=128869677&amp;tab=twitter">
          Posted by <b>62</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=128869677&amp;tab=facebook">
          On <b>1</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #D5E8F0;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=128869677&amp;tab=reddit">
          Reddited by <b>1</b>
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>63</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d6d397f5c677f0-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2119771"> <input type="hidden" name="downloadFileName" value="csp_386_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.386.issue-21%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2119771%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="37" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Himani Vaidya, </li><li class="list-inline-item cited-by__entry__author">Jaroslav Jelinek, </li><li class="list-inline-item cited-by__entry__author">Jean-Pierre J. Issa, </li></ul><span class="cited-by__entry__title">DNA Methylation, Aging, and Cancer, </span><span class="cited-by__entry__series-title">Epigenomes, </span><span class="cited-by__entry__volume"><strong>9</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(18), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3390/epigenomes9020018" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3390/epigenomes9020018</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3390/epigenomes9020018" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Bee Hui Liu, </li><li class="list-inline-item cited-by__entry__author">Miao Liu, </li><li class="list-inline-item cited-by__entry__author">Sridhar Radhakrishnan, </li><li class="list-inline-item cited-by__entry__author">Meng-Yuan Dai, </li><li class="list-inline-item cited-by__entry__author">Chaitanya Kumar Jaladanki, </li><li class="list-inline-item cited-by__entry__author">Chong Gao, </li><li class="list-inline-item cited-by__entry__author">Jing Ping Tang, </li><li class="list-inline-item cited-by__entry__author">Kalpana Kumari, </li><li class="list-inline-item cited-by__entry__author">Mei Lin Go, </li><li class="list-inline-item cited-by__entry__author">Kim Anh L Vu, </li><li class="list-inline-item cited-by__entry__author">Junsu Kwon, </li><li class="list-inline-item cited-by__entry__author">Hyuk-Soo Seo, </li><li class="list-inline-item cited-by__entry__author">Kijun Song, </li><li class="list-inline-item cited-by__entry__author">Xi Tian, </li><li class="list-inline-item cited-by__entry__author">Li Feng, </li><li class="list-inline-item cited-by__entry__author">Justin L Tan, </li><li class="list-inline-item cited-by__entry__author">Arek V Melkonian, </li><li class="list-inline-item cited-by__entry__author">Zhaoji Liu, </li><li class="list-inline-item cited-by__entry__author">Gerburg Wulf, </li><li class="list-inline-item cited-by__entry__author">Haribabu Arthanari, </li><li class="list-inline-item cited-by__entry__author">Jun Qi, </li><li class="list-inline-item cited-by__entry__author">Sirano Dhe-Paganon, </li><li class="list-inline-item cited-by__entry__author">John G Clohessy, </li><li class="list-inline-item cited-by__entry__author">Yeu Khai Choong, </li><li class="list-inline-item cited-by__entry__author">J Sivaraman, </li><li class="list-inline-item cited-by__entry__author">Hao Fan, </li><li class="list-inline-item cited-by__entry__author">Daniel G Tenen, </li><li class="list-inline-item cited-by__entry__author">Li Chai, </li></ul><span class="cited-by__entry__title">Targeting transcription factors through an IMiD independent zinc finger domain, </span><span class="cited-by__entry__series-title">EMBO Molecular Medicine, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1038/s44321-025-00241-3" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1038/s44321-025-00241-3</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1038/s44321-025-00241-3" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Feng Chen, </li><li class="list-inline-item cited-by__entry__author">Lu Chen, </li></ul><span class="cited-by__entry__title">CRISPR/Cas-mediated macromolecular DNA methylation editing: Precision targeting of DNA methyltransferases in cancer therapy, </span><span class="cited-by__entry__series-title">International Journal of Biological Macromolecules, </span><span class="cited-by__entry__volume"><strong>308</strong>, </span><span class="cited-by__entry__page-range">(142401), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ijbiomac.2025.142401" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ijbiomac.2025.142401</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ijbiomac.2025.142401" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Long Cheng, </li><li class="list-inline-item cited-by__entry__author">Yibo Wang, </li><li class="list-inline-item cited-by__entry__author">Ying Zhang, </li></ul><span class="cited-by__entry__title">Dying to survive: harnessing inflammatory cell death for better immunotherapy, </span><span class="cited-by__entry__series-title">Trends in Cancer, </span><span class="cited-by__entry__volume"><strong>11</strong>, </span><span class="cited-by__entry__issue">4, </span><span class="cited-by__entry__page-range">(376-402), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.trecan.2025.01.012" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.trecan.2025.01.012</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.trecan.2025.01.012" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Huifang Bai, </li><li class="list-inline-item cited-by__entry__author">Qianqian Dang, </li><li class="list-inline-item cited-by__entry__author">Guoliang Chen, </li><li class="list-inline-item cited-by__entry__author">Lingfeng Xie, </li><li class="list-inline-item cited-by__entry__author">Saining Wang, </li><li class="list-inline-item cited-by__entry__author">Ning Jiang, </li><li class="list-inline-item cited-by__entry__author">Xiaoxia Wu, </li><li class="list-inline-item cited-by__entry__author">Shuyan Zhang, </li><li class="list-inline-item cited-by__entry__author">Xuelin Wang, </li></ul><span class="cited-by__entry__title">MyD88 inhibitor TJ-M2010-5 alleviates spleen impairment and inflammation by inhibiting the PI3K/miR-136-5p/AKT3 pathway in the early infection of Trichinella spiralis, </span><span class="cited-by__entry__series-title">Veterinary Research, </span><span class="cited-by__entry__volume"><strong>56</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1186/s13567-025-01459-2" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1186/s13567-025-01459-2</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1186/s13567-025-01459-2" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Enrico Checcucci, </li><li class="list-inline-item cited-by__entry__author">Matteo Bauckneht, </li><li class="list-inline-item cited-by__entry__author">Edoardo Cisero, </li><li class="list-inline-item cited-by__entry__author">Gabriele Volpi, </li><li class="list-inline-item cited-by__entry__author">Alessio Rizzo, </li><li class="list-inline-item cited-by__entry__author">Fabio Zattoni, </li><li class="list-inline-item cited-by__entry__author">Lorenzo Bianchi, </li><li class="list-inline-item cited-by__entry__author">Mario De Angelis, </li><li class="list-inline-item cited-by__entry__author">Danilo Cangemi, </li><li class="list-inline-item cited-by__entry__author">Joris Heetman, </li><li class="list-inline-item cited-by__entry__author">Andrea Farolfi, </li><li class="list-inline-item cited-by__entry__author">Federico Piramide, </li><li class="list-inline-item cited-by__entry__author">Sabrina De Cillis, </li><li class="list-inline-item cited-by__entry__author">Daniele Amparore, </li><li class="list-inline-item cited-by__entry__author">Stefano De Luca, </li><li class="list-inline-item cited-by__entry__author">Michele Di Dio, </li><li class="list-inline-item cited-by__entry__author">Fabrizio Dal Moro, </li><li class="list-inline-item cited-by__entry__author">Stefano Fanti, </li><li class="list-inline-item cited-by__entry__author">Riccardo Schiavina, </li><li class="list-inline-item cited-by__entry__author">Alberto Briganti, </li><li class="list-inline-item cited-by__entry__author">Cristian Fiori, </li><li class="list-inline-item cited-by__entry__author">Giorgio Gandaglia, </li><li class="list-inline-item cited-by__entry__author">Francesco Porpiglia, </li></ul><span class="cited-by__entry__title">PSMA PET-targeted Biopsy for Prostate Cancer Diagnosis: Initial Experience From a Multicenter Cohort, </span><span class="cited-by__entry__series-title">Urology, </span><span class="cited-by__entry__volume"><strong>196</strong>, </span><span class="cited-by__entry__page-range">(178-185), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.urology.2024.10.026" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.urology.2024.10.026</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.urology.2024.10.026" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Wenjing Bai, </li><li class="list-inline-item cited-by__entry__author">Jinxin Xu, </li><li class="list-inline-item cited-by__entry__author">Wenbin Gu, </li><li class="list-inline-item cited-by__entry__author">Danyang Wang, </li><li class="list-inline-item cited-by__entry__author">Ying Cui, </li><li class="list-inline-item cited-by__entry__author">Weidong Rong, </li><li class="list-inline-item cited-by__entry__author">Xiaoan Du, </li><li class="list-inline-item cited-by__entry__author">Xiaoxia Li, </li><li class="list-inline-item cited-by__entry__author">Cuicui Xia, </li><li class="list-inline-item cited-by__entry__author">Qingqing Gan, </li><li class="list-inline-item cited-by__entry__author">Guantao He, </li><li class="list-inline-item cited-by__entry__author">Huahui Guo, </li><li class="list-inline-item cited-by__entry__author">Jinfeng Deng, </li><li class="list-inline-item cited-by__entry__author">Yuqiong Wu, </li><li class="list-inline-item cited-by__entry__author">Ray-Whay Chiu Yen, </li><li class="list-inline-item cited-by__entry__author">Srinivasan Yegnasubramanian, </li><li class="list-inline-item cited-by__entry__author">Scott B. Rothbart, </li><li class="list-inline-item cited-by__entry__author">Cheng Luo, </li><li class="list-inline-item cited-by__entry__author">Linping Wu, </li><li class="list-inline-item cited-by__entry__author">Jinsong Liu, </li><li class="list-inline-item cited-by__entry__author">Stephen B. Baylin, </li><li class="list-inline-item cited-by__entry__author">Xiangqian Kong, </li></ul><span class="cited-by__entry__title">Defining ortholog-specific UHRF1 inhibition by STELLA for cancer therapy, </span><span class="cited-by__entry__series-title">Nature Communications, </span><span class="cited-by__entry__volume"><strong>16</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1038/s41467-024-55481-7" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1038/s41467-024-55481-7</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1038/s41467-024-55481-7" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Wanding Zhou, </li><li class="list-inline-item cited-by__entry__author">Yitzhak Reizel, </li></ul><span class="cited-by__entry__title">On correlative and causal links of replicative epimutations, </span><span class="cited-by__entry__series-title">Trends in Genetics, </span><span class="cited-by__entry__volume"><strong>41</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__page-range">(60-75), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.tig.2024.08.008" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.tig.2024.08.008</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.tig.2024.08.008" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Peiyan Wang, </li><li class="list-inline-item cited-by__entry__author">Xiaofei Yu, </li><li class="list-inline-item cited-by__entry__author">Pei Sun, </li><li class="list-inline-item cited-by__entry__author">Keqing Pan, </li><li class="list-inline-item cited-by__entry__author">Jian Sun, </li><li class="list-inline-item cited-by__entry__author">Yiqing Guo, </li><li class="list-inline-item cited-by__entry__author">Zhaochen Liu, </li><li class="list-inline-item cited-by__entry__author">Mengyu Jiao, </li><li class="list-inline-item cited-by__entry__author">Jing Deng, </li><li class="list-inline-item cited-by__entry__author">Hui Zhang, </li></ul><span class="cited-by__entry__title">
              Astaxanthin Increases Tumor Suppressor Gene Expression and Affects Cellular Biological Behavior in Oral Dysplastic Keratinocytes by Regulating
              DNA
              Methylation
            , </span><span class="cited-by__entry__series-title">Journal of Oral Pathology &amp; Medicine, </span><span class="cited-by__entry__volume"><strong>54</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__page-range">(39-48), </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.1111/jop.13593" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1111/jop.13593</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1111/jop.13593" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Qiang Zhou, </li><li class="list-inline-item cited-by__entry__author">Quanlei Xie, </li><li class="list-inline-item cited-by__entry__author">Qiang Liu, </li><li class="list-inline-item cited-by__entry__author">Haojie Wang, </li><li class="list-inline-item cited-by__entry__author">Zhan Zhang, </li><li class="list-inline-item cited-by__entry__author">Zhao Yu, </li><li class="list-inline-item cited-by__entry__author">Qian Guo, </li><li class="list-inline-item cited-by__entry__author">Jie Lin, </li></ul><span class="cited-by__entry__title">DNA methylation inhibitors adverse reaction characteristic analysis: a descriptive analysis from WHO-VigiAccess, </span><span class="cited-by__entry__series-title">Frontiers in Pharmacology, </span><span class="cited-by__entry__volume"><strong>15</strong>, </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.3389/fphar.2024.1470148" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3389/fphar.2024.1470148</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3389/fphar.2024.1470148" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.386.issue-21%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2119771%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2119771" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2119771" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2119771.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2119771_f1.jpg"><img src="/cms/10.1056/NEJMoa2119771/asset/acefb654-f828-49eb-a68e-b8bb6a6aea21/assets/images/large/nejmoa2119771_f1.jpg" height="3078" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Increased <i>SALL4</i> Expression in Patients with Myelodysplastic Syndrome after Treatment with a Hypomethylating Agent.</div><div class="notes"><div role="doc-footnote">Panel A shows a waterfall plot of the log<sub>2</sub> factor change in <i>SALL4</i> expression in 25 patients after four cycles of azacytidine treatment in cohort 1. Panel B shows a waterfall plot of the log<sub>2</sub> factor change in <i>SALL4</i> expression in 43 patients after three to five cycles of treatment with a hypomethylating agent in cohort 2. The term t0 denotes before any cycles of treatment, and t4 after four cycles of treatment. Panel C shows overall survival among patients with <i>SALL4</i> up-regulation and those with <i>SALL4</i> down-regulation in cohort 1, and Panel D shows the corresponding data in cohort 2. In Panels C and D, tick marks indicate censored data. A log-rank test was used to compare survival curves for statistical significance in Panels C and D.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2119771_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2119771_f2.jpg"><img src="/cms/10.1056/NEJMoa2119771/asset/a7bb9a86-fb5d-42f6-8b73-055102d12b4d/assets/images/large/nejmoa2119771_f2.jpg" height="3419" width="2231" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Demethylation of a Critical CpG Island and <i>SALL4</i> Expression in Leukemic Cells Treated with CRISPR-DiR.</div><div class="notes"><div role="doc-footnote">Panel A shows the CpG region within <i>SALL4</i> 5′ untranslated region (5′UTR)–Exon 1–Intron 1. Depicted at the top of the diagram are the 30 CpG residues; depicted below are the four <i>SALL4</i> exons (in blue) and introns (in purple), with the location of the 30 CpG residues in the Exon 1–Intron 1 region. The location of the target of the guide RNA for CRISPR-DiR (clustered regularly interspaced short palindromic repeats–DNA methyltransferase 1 [DNMT1]–interacting RNA) is shown below, targeting CpG number 11. The term dCas9 denotes nuclease-dead Cas9, and sgDiR single-guide DNMT1-interacting RNA. Panel B shows bisulfite sequencing after CRISPR-DiR of HL-60 cells transduced with either a nontargeting negative control guide RNA (DiR_NT) or a targeting guide RNA (DiR_SALL4), leading to demethylation, with higher methylation indicated by redder shading. Panel C shows up-regulation of <i>SALL4</i> transcript (copies per cell assessed by droplet digital polymerase-chain-reaction [ddPCR] assay) in HL-60 cells treated with CRISPR-DiR 8 days after transduction of the CRISPR-DiR. A Wilcoxon rank-sum test was used to evaluate the statistical difference in copies per cell between NT (in three patients) and sgSALL4 (in three patients). Data are shown as means, and error bars indicate the standard deviation.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2119771_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f3"><figure class="graphic"><a class="open-in-viewer" href="#f3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2119771_f3.jpg"><img src="/cms/10.1056/NEJMoa2119771/asset/95f9df45-6d42-490e-bcc5-fb75c3ba00b3/assets/images/large/nejmoa2119771_f3.jpg" height="2671" width="2640" aria-labelledby="f3" loading="lazy"></a><figcaption><div class="caption">Demethylation of a Critical CpG Island and <i>SALL4</i> Expression in Leukemic Cells and Patients with Myelodysplastic Syndrome Treated with a Hypomethylating Agent.</div><div class="notes"><div role="doc-footnote">Panel A shows SALL4 copies per cell assessed by ddPCR assay in HL-60 cells treated with decitabine. A Wilcoxon rank-sum test was used to evaluate the statistical difference in copies per cell between dimethylsulfoxide (DMSO) and decitabine treatments. Data are shown as means, and error bars indicate standard deviations of three biologic replicates. Panel B shows Western blot analysis of HL-60 cells treated with decitabine. Panel C shows methylation profiling in HL-60 cells treated with vehicle alone as compared with those treated with decitabine at a dose of 250 nmol per liter. Treatment with a hypomethylating agent leads to demethylation of <i>SALL4</i> in patients with myelodysplastic syndrome. Panel D shows average methylation across <i>SALL4</i> 5′UTR CpG loci (1 through 11) in patients with myelodysplastic syndrome before any cycles of azacytidine treatment (t0) and after four cycles of such treatment (t4). Red dots indicate patients with up-regulation of <i>SALL4</i> expression after azacytidine treatments, and blue dots indicate patients with down-regulation of <i>SALL4</i> after azacytidine treatments. Methylation values at t0 were compared with methylation values at t4 in each up- and down-regulated group separately. The average difference in methylation between the two time points was calculated with the use of a Wilcoxon matched-pairs signed-rank test (one-tailed) for each up- and down-regulated group separately. Panel E shows methylation changes in six patients with <i>SALL4</i> up-regulation and nine patients with <i>SALL4</i> down-regulation at t0 and t4.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f3"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f3" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2119771_f3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2119771_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2119771/asset/1a30f958-333f-4714-b22c-0353c4245a1f/assets/images/large/nejmoa2119771_t1.jpg" height="3270" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders"><i>SALL4</i> Up-Regulation<br>(N=10)</th><th class="txxr-borders"><i>SALL4</i> Down-Regulation<br>(N=15)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median age (IQR) — yr</td><td class="xxxx-borders shading">59.6 (46.2–61)</td><td class="xxxr-borders shading">59.5 (45–61.5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Sex — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Male</td><td class="xxxx-borders shading">9 (90)</td><td class="xxxr-borders shading">8 (53)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Female</td><td class="xxxx-borders">1 (10)</td><td class="xxxr-borders">7 (47)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">IPSS risk status — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Low or intermediate-1</td><td class="xxxx-borders">1 (10)</td><td class="xxxr-borders">1 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Intermediate-2 or high</td><td class="xxxx-borders shading">9 (90)</td><td class="xxxr-borders shading">13 (87)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">WPSS risk status — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Very low or low</td><td class="xxxx-borders shading">1 (10)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Intermediate</td><td class="xxxx-borders">1 (10)</td><td class="xxxr-borders">2 (13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">High or very high</td><td class="xxxx-borders shading">8 (80)</td><td class="xxxr-borders shading">10 (67)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">IPSS-R risk status — no./total no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Very low</td><td class="xxxx-borders shading">0/9</td><td class="xxxr-borders shading">1/13 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Low</td><td class="xxxx-borders">0/9</td><td class="xxxr-borders">1/13 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Intermediate</td><td class="xxxx-borders shading">2/9 (22)</td><td class="xxxr-borders shading">2/13 (15)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">High</td><td class="xxxx-borders">3/9 (33)</td><td class="xxxr-borders">2/13 (15)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Very high</td><td class="xxxx-borders shading">4/9 (44)</td><td class="xxxr-borders shading">7/13 (54)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Treatment response — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Yes</td><td class="xxxx-borders shading">5 (50)</td><td class="xxxr-borders shading">7 (47)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No</td><td class="xxxx-borders">5 (50)</td><td class="xxxr-borders">8 (53)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median white-cell count (IQR) — per mm<sup>3</sup></td><td class="xxxx-borders shading">2450 (1900–4015)</td><td class="xxxr-borders shading">3320 (2280–10,410)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median absolute neutrophil count (IQR) — per mm<sup>3</sup></td><td class="xxxx-borders">400 (215–1490)</td><td class="xxxr-borders">700 (400–2000)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median hemoglobin level (IQR) — g/dl</td><td class="xxxx-borders shading">9.9 (8.6–10.6)</td><td class="xxxr-borders shading">9.4 (8.7–11.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median platelet count (IQR) — per mm<sup>3</sup></td><td class="xxxx-borders">49,500 (26,750–164,250)</td><td class="xxxr-borders">77,000 (49,000–129,000)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median percentage of blasts in bone marrow aspirate (IQR)</td><td class="xxxx-borders shading">13 (11–15)</td><td class="xxxr-borders shading">12 (3.8–17.8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Cytogenetic features of MDS — no. (%)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Good karyotype</td><td class="xxxx-borders shading">4 (40)</td><td class="xxxr-borders shading">5 (33)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Intermediate karyotype</td><td class="xxxx-borders">2 (20)</td><td class="xxxr-borders">2 (13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Poor karyotype</td><td class="xxxx-borders shading">3 (30)</td><td class="xxxr-borders shading">6 (40)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Mutational profiling — no. (%)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>TET2</i> mutation</td><td class="xxxx-borders shading">1 (10)</td><td class="xxxr-borders shading">6 (40)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>ASXL1</i> mutation</td><td class="xxxx-borders">3 (30)</td><td class="xxxr-borders">6 (40)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>RUNX1</i> mutation</td><td class="xxxx-borders shading">2 (20)</td><td class="xxxr-borders shading">4 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>SETBP1</i> mutation</td><td class="xxxx-borders">2 (20)</td><td class="xxxr-borders">4 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>TP53</i> mutation</td><td class="xxxx-borders shading">3 (30)</td><td class="xxxr-borders shading">2 (13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>ZRSF2</i> mutation</td><td class="xxxx-borders">4 (40)</td><td class="xxxr-borders">1 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>DNMT3A</i> mutation</td><td class="xxxx-borders shading">1 (10)</td><td class="xxxr-borders shading">3 (20)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>SRSF2</i> mutation</td><td class="xxxx-borders">1 (10)</td><td class="xxxr-borders">3 (20)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>SF3B1</i> mutation</td><td class="xxxx-borders shading">1 (10)</td><td class="xxxr-borders shading">2 (13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>U2AF1</i> mutation</td><td class="xxxx-borders">3 (30)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>CEBPA</i> mutation</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">3 (20)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>CBL</i> mutation</td><td class="xxxx-borders">1 (10)</td><td class="xxxr-borders">1 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>ETV6</i> mutation</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">2 (13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>IDH2</i> mutation</td><td class="xxxx-borders">1 (10)</td><td class="xxxr-borders">1 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>NRAS</i> mutation</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">2 (13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>CSF3R</i> mutation</td><td class="xxxx-borders">1 (10)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left"><i>JAK2</i> mutation</td><td class="xbxx-borders shading">1 (10)</td><td class="xbxr-borders shading">0</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">IPSS denotes International Prognostic Scoring System, IPSS-R Revised IPSS, IQR interquartile range, MDS myelodysplastic syndrome, and WPSS World Health Organization Classification-based Prognostic Scoring System.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Three patients (one with <i>SALL4</i> up-regulation and two with <i>SALL4</i> down-regulation) had no metaphase of cytogenetic analysis.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">No mutations in <i>ABL1</i>, <i>BRAF</i>, <i>CALR</i>, <i>EZH2</i>, <i>FLT3</i>, <i>HRAS</i>, <i>IDH1</i>, <i>KIT</i>, <i>KRAS</i>, <i>MPL</i>, <i>NPM1</i>, <i>PTPN11</i>, and <i>WT1</i> were observed in either group.</div></div></div></figcaption></a><figcaption><div class="caption">Baseline Characteristics of 25 Patients Treated with a Hypomethylating Agent in Cohort 1.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2119771_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2119771_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2119771/asset/5b91d533-9cbb-4c35-9092-5180a4987c2d/assets/images/large/nejmoa2119771_t2.jpg" height="3253" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristics</th><th class="txxx-borders"><i>SALL4</i> Up-Regulation<br>(N=13)</th><th class="txxr-borders"><i>SALL4</i> Down-Regulation<br>(N=30)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median age (IQR) — yr</td><td class="xxxx-borders shading">65 (60–69)</td><td class="xxxr-borders shading">62.5 (59.8–67.5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Sex — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Male</td><td class="xxxx-borders shading">11 (85)</td><td class="xxxr-borders shading">17 (57)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Female</td><td class="xxxx-borders">2 (15)</td><td class="xxxr-borders">13 (43)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">IPSS risk status — no./total no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Low or intermediate-1</td><td class="xxxx-borders">8/11 (73)</td><td class="xxxr-borders">17/26 (65)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Intermediate-2 or high</td><td class="xxxx-borders shading">3/11 (27)</td><td class="xxxr-borders shading">9/26 (35)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">WPSS risk status — no./total no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Very low or low</td><td class="xxxx-borders shading">1/11 (9)</td><td class="xxxr-borders shading">2/26 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Intermediate</td><td class="xxxx-borders">2/11 (18)</td><td class="xxxr-borders">9/26 (35)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">High or very high</td><td class="xxxx-borders shading">8/11 (73)</td><td class="xxxr-borders shading">15/26 (58)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">IPSS-R risk status — no./total no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Very low</td><td class="xxxx-borders shading">0/13</td><td class="xxxr-borders shading">1/26 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Low</td><td class="xxxx-borders">1/13 (8)</td><td class="xxxr-borders">1/26 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Intermediate</td><td class="xxxx-borders shading">4/13 (31)</td><td class="xxxr-borders shading">7/26 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">High</td><td class="xxxx-borders">6/13 (46)</td><td class="xxxr-borders">13/26 (50)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Very high</td><td class="xxxx-borders shading">2/13 (15)</td><td class="xxxr-borders shading">4/26 (15)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Treatment response — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Yes</td><td class="xxxx-borders shading">5 (38)</td><td class="xxxr-borders shading">15 (50)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">No</td><td class="xxxx-borders">8 (62)</td><td class="xxxr-borders">15 (50)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median white-cell count (IQR) — per mm<sup>3</sup></td><td class="xxxx-borders shading">2220 (1310–4310)</td><td class="xxxr-borders shading">2180 (1830–2750)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median absolute neutrophil count (IQR) — per mm<sup>3</sup></td><td class="xxxx-borders">780 (330–2240)</td><td class="xxxr-borders">900 (630–1370)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median hemoglobin level (IQR) — g/dl</td><td class="xxxx-borders shading">7.0 (6.2–10.2)</td><td class="xxxr-borders shading">8.1 (7.0–9.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median platelet count (IQR) — per mm<sup>3</sup></td><td class="xxxx-borders">47,000 (31,000–120,000)</td><td class="xxxr-borders">70,000 (38,000–107,000)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median percentage of blasts in bone marrow aspirate (IQR)</td><td class="xxxx-borders shading">6 (5.5–10.8)</td><td class="xxxr-borders shading">7.3 (5.4–11.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Cytogenetic features of MDS — no./total no. (%)<a href="#core-t2fn1" role="doc-noteref">*</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Good karyotype</td><td class="xxxx-borders shading">10/11 (91)</td><td class="xxxr-borders shading">22/26 (85)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Intermediate karyotype</td><td class="xxxx-borders">1/11 (9)</td><td class="xxxr-borders">0/26</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Poor karyotype</td><td class="xxxx-borders shading">0/11</td><td class="xxxr-borders shading">4/26 (15)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Mutational profiling — no./total no. (%)<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>TET2</i> mutation</td><td class="xxxx-borders shading">1/13 (8)</td><td class="xxxr-borders shading">2/28 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>ASXL1</i> mutation</td><td class="xxxx-borders">4/13 (31)</td><td class="xxxr-borders">5/28 (18)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>RUNX1</i> mutation</td><td class="xxxx-borders shading">3/13 (23)</td><td class="xxxr-borders shading">3/28 (11)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>SETBP1</i> mutation</td><td class="xxxx-borders">0/13</td><td class="xxxr-borders">2/28 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>TP53</i> mutation</td><td class="xxxx-borders shading">1/13 (8)</td><td class="xxxr-borders shading">4/28 (14)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>DNMT3A</i> mutation</td><td class="xxxx-borders">0/13</td><td class="xxxr-borders">1/28 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>SRSF2</i> mutation</td><td class="xxxx-borders shading">0/13</td><td class="xxxr-borders shading">1/28 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>SF3B1</i> mutation</td><td class="xxxx-borders">3/13 (23)</td><td class="xxxr-borders">2/28 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>U2AF1</i> mutation</td><td class="xxxx-borders shading">3/13 (23)</td><td class="xxxr-borders shading">4/28 (14)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>CEBPA</i> mutation</td><td class="xxxx-borders">0/13</td><td class="xxxr-borders">1/28 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>IDH2</i> mutation</td><td class="xxxx-borders shading">1/13 (8)</td><td class="xxxr-borders shading">0/28</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>NRAS</i> mutation</td><td class="xxxx-borders">0/13</td><td class="xxxr-borders">3/28 (11)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>JAK2</i> mutation</td><td class="xxxx-borders shading">1/13 (8)</td><td class="xxxr-borders shading">1/28 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>EZH2</i> mutation</td><td class="xxxx-borders">1/13 (8)</td><td class="xxxr-borders">1/28 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>FLT3</i> mutation</td><td class="xxxx-borders shading">1/13 (8)</td><td class="xxxr-borders shading">0/28</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left"><i>IDH1</i> mutation</td><td class="xxxx-borders">1/13 (8)</td><td class="xxxr-borders">2/28 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left"><i>KRAS</i> mutation</td><td class="xxxx-borders shading">1/13 (8)</td><td class="xxxr-borders shading">0/28</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left"><i>NPM1</i> mutation</td><td class="xbxx-borders">0/13</td><td class="xbxr-borders">2/28 (7)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">Two patients with <i>SALL4</i> down-regulation had no metaphase of cytogenetic analysis. Inadequate Giemsa banding in cytogenetic analysis was seen for one patient with <i>SALL4</i> up-regulation and two patients with <i>SALL4</i> down-regulation.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">No mutations in <i>ABL1</i>, <i>BRAF</i>, <i>CALR</i>, <i>CBL</i>, <i>CSF3R</i>, <i>ETV6</i>, <i>KIT</i>, <i>MPL</i>, <i>PTPN11</i>, <i>WT1</i>, and <i>ZRSF2</i> were observed in either group. Two patients with <i>SALL4</i> down-regulation did not undergo next-generation sequencing.</div></div></div></figcaption></a><figcaption><div class="caption">Baseline Characteristics of 43 Patients Treated with a Hypomethylating Agent in Cohort 2.</div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2119771_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2119771</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Taylor SM, Jones PA. Mechanism of action of eukaryotic DNA methyltransferase: use of 5-azacytosine-containing DNA. <em>J Mol Biol</em> 1982;162:679-692.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/0022-2836(82)90395-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/6187927/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1982PV78800010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Mechanism+of+action+of+eukaryotic+DNA+methyltransferase%3A+use+of+5-azacytosine-containing+DNA.&amp;publication_year=1982&amp;journal=J+Mol+Biol&amp;pages=679-692&amp;doi=10.1016%2F0022-2836%2882%2990395-3&amp;pmid=6187927" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Leonhardt H, Page AW, Weier HU, Bestor TH. A targeting sequence directs DNA methyltransferase to sites of DNA replication in mammalian nuclei. <em>Cell</em> 1992;71:865-873.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/0092-8674(92)90561-P" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/1423634/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1992JZ63300015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+targeting+sequence+directs+DNA+methyltransferase+to+sites+of+DNA+replication+in+mammalian+nuclei.&amp;publication_year=1992&amp;journal=Cell&amp;pages=865-873&amp;doi=10.1016%2F0092-8674%2892%2990561-P&amp;pmid=1423634" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Patel K, Dickson J, Din S, Macleod K, Jodrell D, Ramsahoye B. Targeting of 5-aza-2′-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme. <em>Nucleic Acids Res</em> 2010;38:4313-4324.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/nar/gkq187" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20348135/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000280538600018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+of+5-aza-2%E2%80%B2-deoxycytidine+residues+by+chromatin-associated+DNMT1+induces+proteasomal+degradation+of+the+free+enzyme.&amp;publication_year=2010&amp;journal=Nucleic+Acids+Res&amp;pages=4313-4324&amp;doi=10.1093%2Fnar%2Fgkq187&amp;pmid=20348135" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Ghoshal K, Datta J, Majumder S, et al. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. <em>Mol Cell Biol</em> 2005;25:4727-4741.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/MCB.25.11.4727-4741.2005" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15899874/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000229275000035" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=5-Aza-deoxycytidine+induces+selective+degradation+of+DNA+methyltransferase+1+by+a+proteasomal+pathway+that+requires+the+KEN+box%2C+bromo-adjacent+homology+domain%2C+and+nuclear+localization+signal.&amp;publication_year=2005&amp;journal=Mol+Cell+Biol&amp;pages=4727-4741&amp;doi=10.1128%2FMCB.25.11.4727-4741.2005&amp;pmid=15899874" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Bender CM, Zingg JM, Jones PA. DNA methylation as a target for drug design. <em>Pharm Res</em> 1998;15:175-187.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1023/A:1011946030404" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/9523301/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000072331300004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=DNA+methylation+as+a+target+for+drug+design.&amp;publication_year=1998&amp;journal=Pharm+Res&amp;pages=175-187&amp;doi=10.1023%2FA%3A1011946030404&amp;pmid=9523301" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Jüttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. <em>Proc Natl Acad Sci U S A</em> 1994;91:11797-11801.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1073/pnas.91.25.11797" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/7527544/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1994PW70800007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Toxicity+of+5-aza-2%E2%80%B2-deoxycytidine+to+mammalian+cells+is+mediated+primarily+by+covalent+trapping+of+DNA+methyltransferase+rather+than+DNA+demethylation.&amp;publication_year=1994&amp;journal=Proc+Natl+Acad+Sci+U+S+A&amp;pages=11797-11801&amp;doi=10.1073%2Fpnas.91.25.11797&amp;pmid=7527544" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD. DNA methylation inhibitor 5-Aza-2′-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. <em>Mol Cell Biol</em> 2008;28:752-771.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1128/MCB.01799-07" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17991895/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000252283300020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=DNA+methylation+inhibitor+5-Aza-2%E2%80%B2-deoxycytidine+induces+reversible+genome-wide+DNA+damage+that+is+distinctly+influenced+by+DNA+methyltransferases+1+and+3B.&amp;publication_year=2008&amp;journal=Mol+Cell+Biol&amp;pages=752-771&amp;doi=10.1128%2FMCB.01799-07&amp;pmid=17991895" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Li H, Chiappinelli KB, Guzzetta AA, et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. <em>Oncotarget</em> 2014;5:587-598.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.18632/oncotarget.1782" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24583822/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Immune+regulation+by+low+doses+of+the+DNA+methyltransferase+inhibitor+5-azacitidine+in+common+human+epithelial+cancers.&amp;publication_year=2014&amp;journal=Oncotarget&amp;pages=587-598&amp;doi=10.18632%2Foncotarget.1782&amp;pmid=24583822" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Fabre C, Grosjean J, Tailler M, et al. A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts. <em>Cell Cycle</em> 2008;7:2139-2145.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4161/cc.7.14.6268" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18641459/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000258829700012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+novel+effect+of+DNA+methyltransferase+and+histone+deacetylase+inhibitors%3A+NFkappaB+inhibition+in+malignant+myeloblasts.&amp;publication_year=2008&amp;journal=Cell+Cycle&amp;pages=2139-2145&amp;doi=10.4161%2Fcc.7.14.6268&amp;pmid=18641459" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Chiappinelli KB, Strissel PL, Desrichard A, et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. <em>Cell</em> 2015;162:974-986.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cell.2015.07.011" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26317466/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000360589900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inhibiting+DNA+methylation+causes+an+interferon+response+in+cancer+via+dsRNA+including+endogenous+retroviruses.&amp;publication_year=2015&amp;journal=Cell&amp;pages=974-986&amp;doi=10.1016%2Fj.cell.2015.07.011&amp;pmid=26317466" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Ma Y, Cui W, Yang J, et al. SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. <em>Blood</em> 2006;108:2726-2735.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2006-02-001594" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16763212/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000241131700041" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SALL4%2C+a+novel+oncogene%2C+is+constitutively+expressed+in+human+acute+myeloid+leukemia+%28AML%29+and+induces+AML+in+transgenic+mice.&amp;publication_year=2006&amp;journal=Blood&amp;pages=2726-2735&amp;doi=10.1182%2Fblood-2006-02-001594&amp;pmid=16763212" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r11-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and acute myeloid leukemia leukemogenesis </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] acute myeloid leukemia, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] has been shown in previous studies. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Kobayashi D, Kuribayashi K, Tanaka M, Watanabe N. Overexpression of SALL4 in lung cancer and its importance in cell proliferation. <em>Oncol Rep</em> 2011;26:965-970.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21725617/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000294381100027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Overexpression+of+SALL4+in+lung+cancer+and+its+importance+in+cell+proliferation.&amp;publication_year=2011&amp;journal=Oncol+Rep&amp;pages=965-970&amp;pmid=21725617" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Yong KJ, Li A, Ou W-B, et al. Targeting SALL4 by entinostat in lung cancer. <em>Oncotarget</em> 2016;7:75425-75440.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.18632/oncotarget.12251" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27705911/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+SALL4+by+entinostat+in+lung+cancer.&amp;publication_year=2016&amp;journal=Oncotarget&amp;pages=75425-75440&amp;doi=10.18632%2Foncotarget.12251&amp;pmid=27705911" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Yong KJ, Gao C, Lim JSJ, et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. <em>N Engl J Med</em> 2013;368:2266-2276.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_3_15_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2119771&amp;key=10.1056%2FNEJMoa1300297&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23758232/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000320230500002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Oncofetal+gene+SALL4+in+aggressive+hepatocellular+carcinoma.&amp;publication_year=2013&amp;journal=N+Engl+J+Med&amp;pages=2266-2276&amp;doi=10.1056%2FNEJMoa1300297&amp;pmid=23758232" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Elling U, Klasen C, Eisenberger T, Anlag K, Treier M. Murine inner cell mass-derived lineages depend on Sall4 function. <em>Proc Natl Acad Sci U S A</em> 2006;103:16319-16324.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1073/pnas.0607884103" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17060609/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000241879500047" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Murine+inner+cell+mass-derived+lineages+depend+on+Sall4+function.&amp;publication_year=2006&amp;journal=Proc+Natl+Acad+Sci+U+S+A&amp;pages=16319-16324&amp;doi=10.1073%2Fpnas.0607884103&amp;pmid=17060609" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Gao C, Kong NR, Li A, et al. SALL4 is a key transcription regulator in normal human hematopoiesis. <em>Transfusion</em> 2013;53:1037-1049.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1537-2995.2012.03888.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22934838/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000318657200016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SALL4+is+a+key+transcription+regulator+in+normal+human+hematopoiesis.&amp;publication_year=2013&amp;journal=Transfusion&amp;pages=1037-1049&amp;doi=10.1111%2Fj.1537-2995.2012.03888.x&amp;pmid=22934838" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Zhang L, Xu Z, Xu X, et al. SALL4, a novel marker for human gastric carcinogenesis and metastasis. <em>Oncogene</em> 2014;33:5491-5500.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/onc.2013.495" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24276240/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000346087900002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SALL4%2C+a+novel+marker+for+human+gastric+carcinogenesis+and+metastasis.&amp;publication_year=2014&amp;journal=Oncogene&amp;pages=5491-5500&amp;doi=10.1038%2Fonc.2013.495&amp;pmid=24276240" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Gao C, Dimitrov T, Yong KJ, et al. Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex. <em>Blood</em> 2013;121:1413-1421.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2012-04-424275" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23287862/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000321750000026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+transcription+factor+SALL4+in+acute+myeloid+leukemia+by+interrupting+its+interaction+with+an+epigenetic+complex.&amp;publication_year=2013&amp;journal=Blood&amp;pages=1413-1421&amp;doi=10.1182%2Fblood-2012-04-424275&amp;pmid=23287862" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Lu J, Jeong H-W, Kong N, et al. Stem cell factor SALL4 represses the transcriptions of PTEN and SALL1 through an epigenetic repressor complex. <em>PLoS One</em> 2009;4(5):e5577-e5577.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0005577" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19440552/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000266107500008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Stem+cell+factor+SALL4+represses+the+transcriptions+of+PTEN+and+SALL1+through+an+epigenetic+repressor+complex.&amp;publication_year=2009&amp;journal=PLoS+One&amp;pages=e5577-e5577&amp;doi=10.1371%2Fjournal.pone.0005577&amp;pmid=19440552" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Li A, Yang Y, Gao C, et al. A SALL4/MLL/HOXA9 pathway in murine and human myeloid leukemogenesis. <em>J Clin Invest</em> 2013;123:4195-4207.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r20-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1172/JCI62891" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24051379/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000325443100016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+SALL4%2FMLL%2FHOXA9+pathway+in+murine+and+human+myeloid+leukemogenesis.&amp;publication_year=2013&amp;journal=J+Clin+Invest&amp;pages=4195-4207&amp;doi=10.1172%2FJCI62891&amp;pmid=24051379" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r20-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r20-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and activation of other oncogenes. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] acute myeloid leukemia, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Wang F, Guo Y, Chen Q, et al. Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes. <em>J Hematol Oncol</em> 2013;6:73-73.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r21-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/1756-8722-6-73" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24283704/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000325533300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Stem+cell+factor+SALL4%2C+a+potential+prognostic+marker+for+myelodysplastic+syndromes.&amp;publication_year=2013&amp;journal=J+Hematol+Oncol&amp;pages=73-73&amp;doi=10.1186%2F1756-8722-6-73&amp;pmid=24283704" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r21-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in high-risk myelodysplastic syndrome, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] to what has been reported previously. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Lu J, Ma Y, Kong N, et al. Dissecting the role of SALL4, a newly identified stem cell factor, in chronic myelogenous leukemia. <em>Leukemia</em> 2011;25:1211-1213.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/leu.2011.65" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21468036/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000292682600024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dissecting+the+role+of+SALL4%2C+a+newly+identified+stem+cell+factor%2C+in+chronic+myelogenous+leukemia.&amp;publication_year=2011&amp;journal=Leukemia&amp;pages=1211-1213&amp;doi=10.1038%2Fleu.2011.65&amp;pmid=21468036" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Cui W, Kong NR, Ma Y, Amin HM, Lai R, Chai L. Differential expression of the novel oncogene, SALL4, in lymphoma, plasma cell myeloma, and acute lymphoblastic leukemia. <em>Mod Pathol</em> 2006;19:1585-1592.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/modpathol.3800694" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16998462/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000242237700009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Differential+expression+of+the+novel+oncogene%2C+SALL4%2C+in+lymphoma%2C+plasma+cell+myeloma%2C+and+acute+lymphoblastic+leukemia.&amp;publication_year=2006&amp;journal=Mod+Pathol&amp;pages=1585-1592&amp;doi=10.1038%2Fmodpathol.3800694&amp;pmid=16998462" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Shuai X, Zhou D, Shen T, et al. Overexpression of the novel oncogene SALL4 and activation of the Wnt/beta-catenin pathway in myelodysplastic syndromes. <em>Cancer Genet Cytogenet</em> 2009;194:119-124.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cancergencyto.2009.06.006" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19781444/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000270585200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Overexpression+of+the+novel+oncogene+SALL4+and+activation+of+the+Wnt%2Fbeta-catenin+pathway+in+myelodysplastic+syndromes.&amp;publication_year=2009&amp;journal=Cancer+Genet+Cytogenet&amp;pages=119-124&amp;doi=10.1016%2Fj.cancergencyto.2009.06.006&amp;pmid=19781444" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Kwon J, Liu YV, Gao C, et al. Pseudogene-mediated DNA demethylation leads to oncogene activation. <em>Sci Adv</em> 2021;7(40):eabg1695-eabg1695.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r25-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1126/sciadv.abg1695" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34597139/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000703091100003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pseudogene-mediated+DNA+demethylation+leads+to+oncogene+activation.&amp;publication_year=2021&amp;journal=Sci+Adv&amp;pages=eabg1695-eabg1695&amp;doi=10.1126%2Fsciadv.abg1695&amp;pmid=34597139" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r25-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r26" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and reactivation in solid tumors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r25-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and in hepatocellular-carcinoma cell lines </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r25-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] showed effective demethylation ability. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r25-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] neighboring regions could not demethylate. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Fan H, Cui Z, Zhang H, et al. DNA demethylation induces SALL4 gene re-expression in subgroups of hepatocellular carcinoma associated with Hepatitis B or C virus infection. <em>Oncogene</em> 2017;36:2435-2445.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/onc.2016.399" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27797380/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000400268900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=DNA+demethylation+induces+SALL4+gene+re-expression+in+subgroups+of+hepatocellular+carcinoma+associated+with+Hepatitis+B+or+C+virus+infection.&amp;publication_year=2017&amp;journal=Oncogene&amp;pages=2435-2445&amp;doi=10.1038%2Fonc.2016.399&amp;pmid=27797380" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Cazzola M, Malcovati L. Myelodysplastic syndromes — coping with ineffective hematopoiesis. <em>N Engl J Med</em> 2005;352:536-538.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_3_28_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2119771&amp;key=10.1056%2FNEJMp048266&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15703418/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000226862100003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Myelodysplastic+syndromes+%E2%80%94+coping+with+ineffective+hematopoiesis.&amp;publication_year=2005&amp;journal=N+Engl+J+Med&amp;pages=536-538&amp;doi=10.1056%2FNEJMp048266&amp;pmid=15703418" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. <em>Blood</em> 2015;126:9-16.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2015-03-631747" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25931582/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000357696200006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clonal+hematopoiesis+of+indeterminate+potential+and+its+distinction+from+myelodysplastic+syndromes.&amp;publication_year=2015&amp;journal=Blood&amp;pages=9-16&amp;doi=10.1182%2Fblood-2015-03-631747&amp;pmid=25931582" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Voso MT, Leone G, Piciocchi A, et al. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. <em>Ann Oncol</em> 2017;28:1547-1553.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdx154" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28368509/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000404134100021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Feasibility+of+allogeneic+stem-cell+transplantation+after+azacitidine+bridge+in+higher-risk+myelodysplastic+syndromes+and+low+blast+count+acute+myeloid+leukemia%3A+results+of+the+BMT-AZA+prospective+study.&amp;publication_year=2017&amp;journal=Ann+Oncol&amp;pages=1547-1553&amp;doi=10.1093%2Fannonc%2Fmdx154&amp;pmid=28368509" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="core-r30" class="citations"><div class="citation"><div class="citation-content">Falconi G, Fabiani E, Piciocchi A, et al. Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes. <em>Leukemia</em> 2019;33:785-790.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r30-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41375-018-0284-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30291338/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000460406600023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Somatic+mutations+as+markers+of+outcome+after+azacitidine+and+allogeneic+stem+cell+transplantation+in+higher-risk+myelodysplastic+syndromes.&amp;publication_year=2019&amp;journal=Leukemia&amp;pages=785-790&amp;doi=10.1038%2Fs41375-018-0284-9&amp;pmid=30291338" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r30-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r30-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] who were enrolled in the BMT-AZA trial. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r30-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] at diagnosis, mutational profile, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="core-r31" class="citations"><div class="citation"><div class="citation-content">Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. <em>Blood</em> 2016;127:2391-2405.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2016-03-643544" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27069254/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000378333900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+2016+revision+to+the+World+Health+Organization+classification+of+myeloid+neoplasms+and+acute+leukemia.&amp;publication_year=2016&amp;journal=Blood&amp;pages=2391-2405&amp;doi=10.1182%2Fblood-2016-03-643544&amp;pmid=27069254" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="core-r32" class="citations"><div class="citation"><div class="citation-content">Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. <em>Blood</em> 2006;108:419-425.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2005-10-4149" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16609072/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000239129500012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+application+and+proposal+for+modification+of+the+International+Working+Group+%28IWG%29+response+criteria+in+myelodysplasia.&amp;publication_year=2006&amp;journal=Blood&amp;pages=419-425&amp;doi=10.1182%2Fblood-2005-10-4149&amp;pmid=16609072" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="core-r33" class="citations"><div class="citation"><div class="citation-content">Bejar R. Implications of molecular genetic diversity in myelodysplastic syndromes. <em>Curr Opin Hematol</em> 2017;24:73-78.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/MOH.0000000000000313" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27875374/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000393966100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Implications+of+molecular+genetic+diversity+in+myelodysplastic+syndromes.&amp;publication_year=2017&amp;journal=Curr+Opin+Hematol&amp;pages=73-78&amp;doi=10.1097%2FMOH.0000000000000313&amp;pmid=27875374" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="core-r34" class="citations"><div class="citation"><div class="citation-content">Tatetsu H, Kong NR, Chong G, Amabile G, Tenen DG, Chai L. SALL4, the missing link between stem cells, development and cancer. <em>Gene</em> 2016;584:111-119.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r34"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.gene.2016.02.019" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26892498/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000374602700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SALL4%2C+the+missing+link+between+stem+cells%2C+development+and+cancer.&amp;publication_year=2016&amp;journal=Gene&amp;pages=111-119&amp;doi=10.1016%2Fj.gene.2016.02.019&amp;pmid=26892498" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="core-r35" class="citations"><div class="citation"><div class="citation-content">Liu YV, Bassal MA, Jayasinghe MK, et al. Targeted intragenic demethylation initiates chromatin rewiring for gene activation. October 31, 2021 (<a href="https://www.biorxiv.org/content/10.1101/2020.07.16.205922v2">https://www.biorxiv.org/content/10.1101/2020.07.16.205922v2</a>). preprint.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r35-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeted+intragenic+demethylation+initiates+chromatin+rewiring+for+gene+activation.&amp;publication_year=2021" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r35-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r35-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] we applied the CRISPR-DiR technique. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r36-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] interact with and inhibit DNMT1. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r35-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] can achieve site-specific demethylation. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r35-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] sustained up-regulation of gene expression. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="core-r36" class="citations"><div class="citation"><div class="citation-content">Di Ruscio A, Ebralidze AK, Benoukraf T, et al. DNMT1-interacting RNAs block gene-specific DNA methylation. <em>Nature</em> 2013;503:371-376.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r36-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature12598" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24107992/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000327163200035" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=DNMT1-interacting+RNAs+block+gene-specific+DNA+methylation.&amp;publication_year=2013&amp;journal=Nature&amp;pages=371-376&amp;doi=10.1038%2Fnature12598&amp;pmid=24107992" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r36-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r36-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] demethylation by blocking DNMT1 activity </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r36-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] interact with and inhibit DNMT1. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">37.</div><div id="core-r37" class="citations"><div class="citation"><div class="citation-content">Mozessohn L, Cheung MC, Fallahpour S, et al. Azacitidine in the ‘real-world’: an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada. <em>Br J Haematol</em> 2018;181:803-815.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r37"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjh.15273" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29767427/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000435268600011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Azacitidine+in+the+%E2%80%98real-world%E2%80%99%3A+an+evaluation+of+1101+higher-risk+myelodysplastic+syndrome%2Flow+blast+count+acute+myeloid+leukaemia+patients+in+Ontario%2C+Canada.&amp;publication_year=2018&amp;journal=Br+J+Haematol&amp;pages=803-815&amp;doi=10.1111%2Fbjh.15273&amp;pmid=29767427" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">38.</div><div id="core-r38" class="citations"><div class="citation"><div class="citation-content">Prébet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. <em>J Clin Oncol</em> 2011;29:3322-3327.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2011.35.8135" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21788559/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000294008500027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Outcome+of+high-risk+myelodysplastic+syndrome+after+azacitidine+treatment+failure.&amp;publication_year=2011&amp;journal=J+Clin+Oncol&amp;pages=3322-3327&amp;doi=10.1200%2FJCO.2011.35.8135&amp;pmid=21788559" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">39.</div><div id="core-r39" class="citations"><div class="citation"><div class="citation-content">Yang J, Gao C, Liu M, et al. Targeting an inducible SALL4-mediated cancer vulnerability with sequential therapy. <em>Cancer Res</em> 2021;81:6018-6028.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r39"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/0008-5472.CAN-21-0030" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34593523/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000726534400001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Targeting+an+inducible+SALL4-mediated+cancer+vulnerability+with+sequential+therapy.&amp;publication_year=2021&amp;journal=Cancer+Res&amp;pages=6018-6028&amp;doi=10.1158%2F0008-5472.CAN-21-0030&amp;pmid=34593523" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Aug 03, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2208134" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Oncogene Up-Regulation after Hypomethylating Therapy</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Manchester, New Hampshire</span></div><div><span>Gastroenterology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/889103/gastroenterologist-needed-for-elliot-hospital-manchester-nh-1-hr-to-boston-/?query=fjwp&amp;rid=484217">Gastroenterologist Needed for Elliot Hospital, Manchester NH (1-hr to Boston)</a></div></div><div class="nejm-widget_item"><div><span> Iowa City, Iowa</span></div><div><span>Hematology / Oncology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/893408/gastrointestinal-oncologist/?query=fjwp&amp;rid=778673">GASTROINTESTINAL ONCOLOGIST</a></div></div><div class="nejm-widget_item"><div><span> San Antonio, Texas</span></div><div><span>Hospitalist</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/880974/nocturnist-hospitalist-physician-wellmed-networks-inc-san-antonio-tx/?query=fjwf&amp;rid=220874">Nocturnist Hospitalist Physician - WellMed Networks, Inc - San Antonio, TX</a></div></div><div class="nejm-widget_item"><div><span> New York</span></div><div><span>Radiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/836138/musculoskeletal-radiologist/?query=fjwp&amp;rid=3059">Musculoskeletal Radiologist</a></div></div><div class="nejm-widget_item"><div><span> Cleveland, Ohio</span></div><div><span>Surgery, General</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/877997/vascular-surgeons-cleveland-clinic-health-system-west-side/?query=fjwf&amp;rid=2201">Vascular Surgeons Cleveland Clinic Health System West Side</a></div></div><div class="nejm-widget_item"><div><span> Philadelphia, Pennsylvania</span></div><div><span>Anesthesiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/888010/anesthesiologist-faculty-and-community-opportunities-with-jefferson-philadelphia-pa/?query=fjwf&amp;rid=271428">Anesthesiologist - Faculty and Community Opportunities with Jefferson - Philadelphia, PA</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128720&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejmai%2Fregister%2Faifallpdf24%3Fpromo%3DOAFQF4NA%26query%3Dcm-rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Daifallpdf24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2119771&amp;pubId=41283451&amp;placeholderId=101337&amp;productId=1007" target="_blank"><img src="/sda/128720/NEJ-AI-Fall24-300x250---002.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d6d397f5c677f0-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d6d397f5c677f0-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d6d397f5c677f0-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$899182354$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$899182354$--><div class="skeleton-card"><loading-skeleton animation="progress" height="3.125rem" variant="rect"></loading-skeleton><loading-skeleton animation="progress" height="1.25rem" width="95%" variant="rect"></loading-skeleton><loading-skeleton animation="progress" height="2.5rem" width="85%" variant="rect"></loading-skeleton><loading-skeleton animation="progress" height="1.25rem" width="85%" variant="rect"></loading-skeleton></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2119771?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2119771" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2119771.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2119771"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2201171" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Tranexamic Acid in Patients Undergoing Noncardiac Surgery</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2203315" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2119771_f1.jpg"><img src="/cms/10.1056/NEJMoa2119771/asset/acefb654-f828-49eb-a68e-b8bb6a6aea21/assets/images/large/nejmoa2119771_f1.jpg" height="3078" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Increased <i>SALL4</i> Expression in Patients with Myelodysplastic Syndrome after Treatment with a Hypomethylating Agent.</div><div class="notes"><div role="doc-footnote">Panel A shows a waterfall plot of the log<sub>2</sub> factor change in <i>SALL4</i> expression in 25 patients after four cycles of azacytidine treatment in cohort 1. Panel B shows a waterfall plot of the log<sub>2</sub> factor change in <i>SALL4</i> expression in 43 patients after three to five cycles of treatment with a hypomethylating agent in cohort 2. The term t0 denotes before any cycles of treatment, and t4 after four cycles of treatment. Panel C shows overall survival among patients with <i>SALL4</i> up-regulation and those with <i>SALL4</i> down-regulation in cohort 1, and Panel D shows the corresponding data in cohort 2. In Panels C and D, tick marks indicate censored data. A log-rank test was used to compare survival curves for statistical significance in Panels C and D.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2119771_f2.jpg"><img src="/cms/10.1056/NEJMoa2119771/asset/a7bb9a86-fb5d-42f6-8b73-055102d12b4d/assets/images/large/nejmoa2119771_f2.jpg" height="3419" width="2231" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Demethylation of a Critical CpG Island and <i>SALL4</i> Expression in Leukemic Cells Treated with CRISPR-DiR.</div><div class="notes"><div role="doc-footnote">Panel A shows the CpG region within <i>SALL4</i> 5′ untranslated region (5′UTR)–Exon 1–Intron 1. Depicted at the top of the diagram are the 30 CpG residues; depicted below are the four <i>SALL4</i> exons (in blue) and introns (in purple), with the location of the 30 CpG residues in the Exon 1–Intron 1 region. The location of the target of the guide RNA for CRISPR-DiR (clustered regularly interspaced short palindromic repeats–DNA methyltransferase 1 [DNMT1]–interacting RNA) is shown below, targeting CpG number 11. The term dCas9 denotes nuclease-dead Cas9, and sgDiR single-guide DNMT1-interacting RNA. Panel B shows bisulfite sequencing after CRISPR-DiR of HL-60 cells transduced with either a nontargeting negative control guide RNA (DiR_NT) or a targeting guide RNA (DiR_SALL4), leading to demethylation, with higher methylation indicated by redder shading. Panel C shows up-regulation of <i>SALL4</i> transcript (copies per cell assessed by droplet digital polymerase-chain-reaction [ddPCR] assay) in HL-60 cells treated with CRISPR-DiR 8 days after transduction of the CRISPR-DiR. A Wilcoxon rank-sum test was used to evaluate the statistical difference in copies per cell between NT (in three patients) and sgSALL4 (in three patients). Data are shown as means, and error bars indicate the standard deviation.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f3" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2119771_f3.jpg"><img src="/cms/10.1056/NEJMoa2119771/asset/95f9df45-6d42-490e-bcc5-fb75c3ba00b3/assets/images/large/nejmoa2119771_f3.jpg" height="2671" width="2640" aria-labelledby="f3" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 3</div><div class="fv__item__description"><figcaption><div class="caption">Demethylation of a Critical CpG Island and <i>SALL4</i> Expression in Leukemic Cells and Patients with Myelodysplastic Syndrome Treated with a Hypomethylating Agent.</div><div class="notes"><div role="doc-footnote">Panel A shows SALL4 copies per cell assessed by ddPCR assay in HL-60 cells treated with decitabine. A Wilcoxon rank-sum test was used to evaluate the statistical difference in copies per cell between dimethylsulfoxide (DMSO) and decitabine treatments. Data are shown as means, and error bars indicate standard deviations of three biologic replicates. Panel B shows Western blot analysis of HL-60 cells treated with decitabine. Panel C shows methylation profiling in HL-60 cells treated with vehicle alone as compared with those treated with decitabine at a dose of 250 nmol per liter. Treatment with a hypomethylating agent leads to demethylation of <i>SALL4</i> in patients with myelodysplastic syndrome. Panel D shows average methylation across <i>SALL4</i> 5′UTR CpG loci (1 through 11) in patients with myelodysplastic syndrome before any cycles of azacytidine treatment (t0) and after four cycles of such treatment (t4). Red dots indicate patients with up-regulation of <i>SALL4</i> expression after azacytidine treatments, and blue dots indicate patients with down-regulation of <i>SALL4</i> after azacytidine treatments. Methylation values at t0 were compared with methylation values at t4 in each up- and down-regulated group separately. The average difference in methylation between the two time points was calculated with the use of a Wilcoxon matched-pairs signed-rank test (one-tailed) for each up- and down-regulated group separately. Panel E shows methylation changes in six patients with <i>SALL4</i> up-regulation and nine patients with <i>SALL4</i> down-regulation at t0 and t4.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Baseline Characteristics of 25 Patients Treated with a Hypomethylating Agent in Cohort 1.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Baseline Characteristics of 43 Patients Treated with a Hypomethylating Agent in Cohort 2.</div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/386/21" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 386 No. 21</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">May 26, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2201171" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Tranexamic Acid in Patients Undergoing Noncardiac Surgery</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">P.J. Devereaux and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">May 26, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2203315" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">C.B. Creech and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">May 26, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2202170" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">P.M. Forde and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2119771%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2119771&amp;pubId=41283451&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2119771%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2119771&amp;pubId=41283451&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id08384180519414441" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d6d397f5c677f0-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d6d397f5c677f0-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d6d397f5c677f0-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d6d397f5c677f0-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d6d397f5c677f0-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d6d397f5c677f0-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d6d397f5c677f0-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d6d397f5c677f0-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d6d397f5c677f0-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d6d397f5c677f0-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d6d397eed777f0',t:'MTc0OTUzNzA5NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d6d397eed777f0&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" data-transactionid="qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" id="captureIFrame_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" target="captureIFrame_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" name="capture_screen"><input id="capture_signIn_js_version_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" name="js_version"><input id="capture_signIn_transactionId_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" data-capturefield="undefined" value="qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" type="hidden" class="capture_transactionId_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" name="capture_transactionId"><input id="capture_signIn_form_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" name="form"><input id="capture_signIn_flow_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" name="flow"><input id="capture_signIn_client_id_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" name="client_id"><input id="capture_signIn_redirect_uri_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" name="redirect_uri"><input id="capture_signIn_response_type_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" name="response_type"><input id="capture_signIn_flow_version_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" name="flow_version"><input id="capture_signIn_settings_version_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" name="settings_version"><input id="capture_signIn_locale_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" name="locale"><input id="capture_signIn_recaptcha_version_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_qrssytdyoxalz73qhj5nck0zv7dy526y18u8eqte" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div><div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><diu-tmfwumidlhqn></diu-tmfwumidlhqn><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2119771?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=3-10"></script></body></html>